CN101274928A - 3-取代的-4-嘧啶酮衍生物 - Google Patents
3-取代的-4-嘧啶酮衍生物 Download PDFInfo
- Publication number
- CN101274928A CN101274928A CNA2008100076698A CN200810007669A CN101274928A CN 101274928 A CN101274928 A CN 101274928A CN A2008100076698 A CNA2008100076698 A CN A2008100076698A CN 200810007669 A CN200810007669 A CN 200810007669A CN 101274928 A CN101274928 A CN 101274928A
- Authority
- CN
- China
- Prior art keywords
- ring
- methyl
- pyridin
- pyrimidin
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 3-substituted-4-pyrimidinone Chemical class 0.000 title description 155
- 150000003839 salts Chemical class 0.000 claims abstract description 53
- 239000012453 solvate Substances 0.000 claims abstract description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 22
- 125000004429 atom Chemical group 0.000 claims abstract description 21
- 150000008318 pyrimidones Chemical class 0.000 claims abstract description 19
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 108010061506 tau-protein kinase Proteins 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 210000004556 brain Anatomy 0.000 claims description 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 7
- 206010014599 encephalitis Diseases 0.000 claims description 6
- 230000000302 ischemic effect Effects 0.000 claims description 6
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 231100000360 alopecia Toxicity 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- NXCQEVQGDRISRL-UHFFFAOYSA-N 2-(2-benzoylmorpholin-4-yl)-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C(=O)C=2C=CC=CC=2)=NC=1C1=CC=NC=C1 NXCQEVQGDRISRL-UHFFFAOYSA-N 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- KVAYRHJOQRDMSZ-UHFFFAOYSA-N 2-[2-(2-methoxybenzoyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC=C1C(=O)C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 KVAYRHJOQRDMSZ-UHFFFAOYSA-N 0.000 claims description 2
- CALUEJCGPKAZAW-UHFFFAOYSA-N 2-[2-(4-fluorobenzoyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C(=O)C=2C=CC(F)=CC=2)=NC=1C1=CC=NC=C1 CALUEJCGPKAZAW-UHFFFAOYSA-N 0.000 claims description 2
- YDQJQHCXSRFPAT-UHFFFAOYSA-N 2-[2-(4-methoxybenzoyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 YDQJQHCXSRFPAT-UHFFFAOYSA-N 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 150000002790 naphthalenes Chemical class 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 63
- 125000001624 naphthyl group Chemical group 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 125000004434 sulfur atom Chemical group 0.000 abstract description 13
- 125000004430 oxygen atom Chemical group O* 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract description 7
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract description 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract description 5
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 84
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 125000001424 substituent group Chemical group 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 102100037495 Thiamin pyrophosphokinase 1 Human genes 0.000 description 18
- 101710203399 Thiamin pyrophosphokinase 1 Proteins 0.000 description 18
- 150000001412 amines Chemical class 0.000 description 18
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 208000024827 Alzheimer disease Diseases 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 150000001805 chlorine compounds Chemical class 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 150000004677 hydrates Chemical class 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- QUBIWSDNYCMADB-UHFFFAOYSA-N 2-chloro-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound O=C1N(C)C(Cl)=NC(C=2C=CN=CC=2)=C1 QUBIWSDNYCMADB-UHFFFAOYSA-N 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 206010029350 Neurotoxicity Diseases 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 206010044221 Toxic encephalopathy Diseases 0.000 description 5
- 239000005456 alcohol based solvent Substances 0.000 description 5
- 239000004210 ether based solvent Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000008282 halocarbons Chemical class 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 125000005921 isopentoxy group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007135 neurotoxicity Effects 0.000 description 5
- 231100000228 neurotoxicity Toxicity 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 239000002798 polar solvent Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010024238 Leptospirosis Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 4
- 102000013498 tau Proteins Human genes 0.000 description 4
- 108010026424 tau Proteins Proteins 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 description 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000012320 chlorinating reagent Substances 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VUIUUPMMRIZOPM-UHFFFAOYSA-N (4-benzylmorpholin-2-yl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C(OCC1)CN1CC1=CC=CC=C1 VUIUUPMMRIZOPM-UHFFFAOYSA-N 0.000 description 2
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical group C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- BXQNSPXDWSNUKE-UHFFFAOYSA-N 1,3-benzothiazole 1-oxide Chemical group C1=CC=C2S(=O)C=NC2=C1 BXQNSPXDWSNUKE-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- DXFCUZGJPYQFIU-UHFFFAOYSA-N 2-(3-benzoylpiperidin-1-yl)-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(CCC2)C(=O)C=2C=CC=CC=2)=NC=1C1=CC=NC=C1 DXFCUZGJPYQFIU-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- AMMSSQAWYDICPE-LJQANCHMSA-N 2-[(2s)-2-(4-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1[C@@H]1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 AMMSSQAWYDICPE-LJQANCHMSA-N 0.000 description 2
- CIJJVZNLCRZZKK-UHFFFAOYSA-N 2-[4-(4-chlorobenzoyl)piperidin-1-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CCC(CC2)C(=O)C=2C=CC(Cl)=CC=2)=NC=1C1=CC=NC=C1 CIJJVZNLCRZZKK-UHFFFAOYSA-N 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical group C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
- MXLBEFRKZYPNQP-UHFFFAOYSA-N 3-methyl-6-pyridin-4-yl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound N1C(=S)N(C)C(=O)C=C1C1=CC=NC=C1 MXLBEFRKZYPNQP-UHFFFAOYSA-N 0.000 description 2
- WPPHMBKSJVDIFZ-UHFFFAOYSA-N 3H-1,2-benzodioxole Chemical group C1=CC=C2COOC2=C1 WPPHMBKSJVDIFZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- LVPUHRZVTCJFMU-UHFFFAOYSA-N CN1C(=NC(=CC1=O)C1=CC=NC=C1)NCOC1=CC=CC=C1 Chemical compound CN1C(=NC(=CC1=O)C1=CC=NC=C1)NCOC1=CC=CC=C1 LVPUHRZVTCJFMU-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical group C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- WNVNOPSKZKBQCW-UHFFFAOYSA-N morpholin-2-yl(phenyl)methanone;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(=O)C1CNCCO1 WNVNOPSKZKBQCW-UHFFFAOYSA-N 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 125000005543 phthalimide group Chemical group 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical group N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 150000003527 tetrahydropyrans Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- ZJGHNDHUXWVIMU-RFVHGSKJSA-N (2s)-2-(4-methoxyphenyl)morpholine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1[C@@H]1OCCNC1 ZJGHNDHUXWVIMU-RFVHGSKJSA-N 0.000 description 1
- QJSPOHXMUQSIKX-UHFFFAOYSA-N (4-chlorophenyl)-piperidin-1-ylmethanone;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(=O)N1CCCCC1 QJSPOHXMUQSIKX-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical group C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- NXILIHONWRXHFA-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCC(C(O)=O)C1 NXILIHONWRXHFA-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- RPMITZJMOPAUMG-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1H-benzo[7]annulene Chemical group C1=CC=CC2CCCCC2=C1 RPMITZJMOPAUMG-UHFFFAOYSA-N 0.000 description 1
- WLHBQWNPCMVPQZ-UHFFFAOYSA-N 2-(4-benzoylpiperidin-1-yl)-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CCC(CC2)C(=O)C=2C=CC=CC=2)=NC=1C1=CC=NC=C1 WLHBQWNPCMVPQZ-UHFFFAOYSA-N 0.000 description 1
- AURHLFJTDHUQKU-FQEVSTJZSA-N 2-[(2s)-2-(1-benzofuran-2-yl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@H](OCC2)C=2OC3=CC=CC=C3C=2)=NC=1C1=CC=NC=C1 AURHLFJTDHUQKU-FQEVSTJZSA-N 0.000 description 1
- OYTNQXCKJVXNFQ-GOSISDBHSA-N 2-[(2s)-2-(2,4-difluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=NC=C1 OYTNQXCKJVXNFQ-GOSISDBHSA-N 0.000 description 1
- NCPUWAGCDXDIPX-HXUWFJFHSA-N 2-[(2s)-2-(2,4-dimethoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC(OC)=CC=C1[C@@H]1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 NCPUWAGCDXDIPX-HXUWFJFHSA-N 0.000 description 1
- MBVYGBUUQIDTAQ-HXUWFJFHSA-N 2-[(2s)-2-(2,5-dimethoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=C(OC)C([C@@H]2OCCN(C2)C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)=C1 MBVYGBUUQIDTAQ-HXUWFJFHSA-N 0.000 description 1
- MBEKVLSSEYOCSP-QGZVFWFLSA-N 2-[(2s)-2-(2,6-dichlorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C(=CC=CC=2Cl)Cl)=NC=1C1=CC=NC=C1 MBEKVLSSEYOCSP-QGZVFWFLSA-N 0.000 description 1
- UUJZZJCEWDZFCY-QGZVFWFLSA-N 2-[(2s)-2-(2,6-difluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C(=CC=CC=2F)F)=NC=1C1=CC=NC=C1 UUJZZJCEWDZFCY-QGZVFWFLSA-N 0.000 description 1
- ITAUXPSETNVANZ-LJQANCHMSA-N 2-[(2s)-2-(2,6-dimethoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC(OC)=C1[C@@H]1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 ITAUXPSETNVANZ-LJQANCHMSA-N 0.000 description 1
- BDBDSBMMKVJRJC-QGZVFWFLSA-N 2-[(2s)-2-(2-chloro-6-fluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C(=CC=CC=2F)Cl)=NC=1C1=CC=NC=C1 BDBDSBMMKVJRJC-QGZVFWFLSA-N 0.000 description 1
- JFCBDPQANHNOJC-GOSISDBHSA-N 2-[(2s)-2-(2-chlorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C(=CC=CC=2)Cl)=NC=1C1=CC=NC=C1 JFCBDPQANHNOJC-GOSISDBHSA-N 0.000 description 1
- TWBJZXRIHWILSP-GOSISDBHSA-N 2-[(2s)-2-(2-fluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C(=CC=CC=2)F)=NC=1C1=CC=NC=C1 TWBJZXRIHWILSP-GOSISDBHSA-N 0.000 description 1
- RXCKTOIDABXJLT-LJQANCHMSA-N 2-[(2s)-2-(2-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC=C1[C@@H]1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 RXCKTOIDABXJLT-LJQANCHMSA-N 0.000 description 1
- NUWBPSCILGWYJD-GOSISDBHSA-N 2-[(2s)-2-(3-bromophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C=C(Br)C=CC=2)=NC=1C1=CC=NC=C1 NUWBPSCILGWYJD-GOSISDBHSA-N 0.000 description 1
- WYVWRIBBJCVZBU-LJQANCHMSA-N 2-[(2s)-2-(3-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC([C@@H]2OCCN(C2)C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)=C1 WYVWRIBBJCVZBU-LJQANCHMSA-N 0.000 description 1
- PDXVBCFBVCQTFC-GOSISDBHSA-N 2-[(2s)-2-(4-bromophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C=CC(Br)=CC=2)=NC=1C1=CC=NC=C1 PDXVBCFBVCQTFC-GOSISDBHSA-N 0.000 description 1
- RSGNGUPSUUTVML-LJQANCHMSA-N 2-[(2s)-2-(4-fluoro-2-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC(F)=CC=C1[C@@H]1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 RSGNGUPSUUTVML-LJQANCHMSA-N 0.000 description 1
- FZPYWVVOFIWWAQ-GOSISDBHSA-N 2-[(2s)-2-(4-fluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C=CC(F)=CC=2)=NC=1C1=CC=NC=C1 FZPYWVVOFIWWAQ-GOSISDBHSA-N 0.000 description 1
- AURHLFJTDHUQKU-UHFFFAOYSA-N 2-[2-(1-benzofuran-2-yl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2OC3=CC=CC=C3C=2)=NC=1C1=CC=NC=C1 AURHLFJTDHUQKU-UHFFFAOYSA-N 0.000 description 1
- SYGZDGRPYWLFGC-UHFFFAOYSA-N 2-[2-(2,3-dihydro-1-benzofuran-7-yl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=3OCCC=3C=CC=2)=NC=1C1=CC=NC=C1 SYGZDGRPYWLFGC-UHFFFAOYSA-N 0.000 description 1
- SKSYOLBNGGRQAC-UHFFFAOYSA-N 2-[2-(2,4-difluoro-6-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC(F)=CC(F)=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 SKSYOLBNGGRQAC-UHFFFAOYSA-N 0.000 description 1
- OYTNQXCKJVXNFQ-UHFFFAOYSA-N 2-[2-(2,4-difluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=NC=C1 OYTNQXCKJVXNFQ-UHFFFAOYSA-N 0.000 description 1
- NCPUWAGCDXDIPX-UHFFFAOYSA-N 2-[2-(2,4-dimethoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC(OC)=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 NCPUWAGCDXDIPX-UHFFFAOYSA-N 0.000 description 1
- MBVYGBUUQIDTAQ-UHFFFAOYSA-N 2-[2-(2,5-dimethoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=C(OC)C(C2OCCN(C2)C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)=C1 MBVYGBUUQIDTAQ-UHFFFAOYSA-N 0.000 description 1
- MBEKVLSSEYOCSP-UHFFFAOYSA-N 2-[2-(2,6-dichlorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2Cl)Cl)=NC=1C1=CC=NC=C1 MBEKVLSSEYOCSP-UHFFFAOYSA-N 0.000 description 1
- UUJZZJCEWDZFCY-UHFFFAOYSA-N 2-[2-(2,6-difluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2F)F)=NC=1C1=CC=NC=C1 UUJZZJCEWDZFCY-UHFFFAOYSA-N 0.000 description 1
- ITAUXPSETNVANZ-UHFFFAOYSA-N 2-[2-(2,6-dimethoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC(OC)=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 ITAUXPSETNVANZ-UHFFFAOYSA-N 0.000 description 1
- GXTQJAFEQFYDTA-UHFFFAOYSA-N 2-[2-(2-bromo-4-fluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC(F)=CC=2)Br)=NC=1C1=CC=NC=C1 GXTQJAFEQFYDTA-UHFFFAOYSA-N 0.000 description 1
- JHNWKTOHLFPYOV-UHFFFAOYSA-N 2-[2-(2-bromophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2)Br)=NC=1C1=CC=NC=C1 JHNWKTOHLFPYOV-UHFFFAOYSA-N 0.000 description 1
- DBJVGNLCJPYSTH-UHFFFAOYSA-N 2-[2-(2-chloro-4,5-difluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC(F)=C(F)C=2)Cl)=NC=1C1=CC=NC=C1 DBJVGNLCJPYSTH-UHFFFAOYSA-N 0.000 description 1
- BDBDSBMMKVJRJC-UHFFFAOYSA-N 2-[2-(2-chloro-6-fluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2F)Cl)=NC=1C1=CC=NC=C1 BDBDSBMMKVJRJC-UHFFFAOYSA-N 0.000 description 1
- JFCBDPQANHNOJC-UHFFFAOYSA-N 2-[2-(2-chlorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2)Cl)=NC=1C1=CC=NC=C1 JFCBDPQANHNOJC-UHFFFAOYSA-N 0.000 description 1
- WZTPCRSJMDJKHR-UHFFFAOYSA-N 2-[2-(2-ethoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound CCOC1=CC=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 WZTPCRSJMDJKHR-UHFFFAOYSA-N 0.000 description 1
- TWBJZXRIHWILSP-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2)F)=NC=1C1=CC=NC=C1 TWBJZXRIHWILSP-UHFFFAOYSA-N 0.000 description 1
- RXCKTOIDABXJLT-UHFFFAOYSA-N 2-[2-(2-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 RXCKTOIDABXJLT-UHFFFAOYSA-N 0.000 description 1
- NUWBPSCILGWYJD-UHFFFAOYSA-N 2-[2-(3-bromophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=C(Br)C=CC=2)=NC=1C1=CC=NC=C1 NUWBPSCILGWYJD-UHFFFAOYSA-N 0.000 description 1
- BBNWEEMYFMVCSH-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=C(Cl)C=CC=2)=NC=1C1=CC=NC=C1 BBNWEEMYFMVCSH-UHFFFAOYSA-N 0.000 description 1
- WYVWRIBBJCVZBU-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC(C2OCCN(C2)C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)=C1 WYVWRIBBJCVZBU-UHFFFAOYSA-N 0.000 description 1
- PDXVBCFBVCQTFC-UHFFFAOYSA-N 2-[2-(4-bromophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=CC(Br)=CC=2)=NC=1C1=CC=NC=C1 PDXVBCFBVCQTFC-UHFFFAOYSA-N 0.000 description 1
- OYKJQEWCPQEKMJ-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=CC(Cl)=CC=2)=NC=1C1=CC=NC=C1 OYKJQEWCPQEKMJ-UHFFFAOYSA-N 0.000 description 1
- RSGNGUPSUUTVML-UHFFFAOYSA-N 2-[2-(4-fluoro-2-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC(F)=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 RSGNGUPSUUTVML-UHFFFAOYSA-N 0.000 description 1
- IFUFVUIPBUYGRL-UHFFFAOYSA-N 2-[2-(4-fluoro-3-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C1=C(F)C(OC)=CC(C2OCCN(C2)C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)=C1 IFUFVUIPBUYGRL-UHFFFAOYSA-N 0.000 description 1
- FZPYWVVOFIWWAQ-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=CC(F)=CC=2)=NC=1C1=CC=NC=C1 FZPYWVVOFIWWAQ-UHFFFAOYSA-N 0.000 description 1
- AMMSSQAWYDICPE-UHFFFAOYSA-N 2-[2-(4-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 AMMSSQAWYDICPE-UHFFFAOYSA-N 0.000 description 1
- CUXNPXKKUREEDX-UHFFFAOYSA-N 2-[2-(5-fluoro-2-methoxyphenyl)morpholin-4-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=C(F)C=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 CUXNPXKKUREEDX-UHFFFAOYSA-N 0.000 description 1
- DRXZVONIXATJOJ-UHFFFAOYSA-N 2-[3-(2-methoxybenzoyl)piperidin-1-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound COC1=CC=CC=C1C(=O)C1CN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)CCC1 DRXZVONIXATJOJ-UHFFFAOYSA-N 0.000 description 1
- JCLHBDAOXDUXLU-UHFFFAOYSA-N 2-[3-(4-fluorobenzoyl)piperidin-1-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(CCC2)C(=O)C=2C=CC(F)=CC=2)=NC=1C1=CC=NC=C1 JCLHBDAOXDUXLU-UHFFFAOYSA-N 0.000 description 1
- VTGRPKNKOAIBPL-UHFFFAOYSA-N 2-[3-(4-methoxybenzoyl)piperidin-1-yl]-3-methyl-6-pyridin-4-ylpyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1CN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)CCC1 VTGRPKNKOAIBPL-UHFFFAOYSA-N 0.000 description 1
- RBROMNGHKPOKNG-UHFFFAOYSA-N 2-[4-(1-methyl-6-oxo-4-pyridin-4-ylpyrimidin-2-yl)morpholin-2-yl]benzonitrile Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2)C#N)=NC=1C1=CC=NC=C1 RBROMNGHKPOKNG-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical group C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- SADPCIINLASURY-UHFFFAOYSA-N 2-morpholin-4-ylethanesulfonic acid;sodium Chemical compound [Na].OS(=O)(=O)CCN1CCOCC1 SADPCIINLASURY-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- GTZSJDLMBKRWKP-LJQANCHMSA-N 3-[(2s)-4-(1-methyl-6-oxo-4-pyridin-4-ylpyrimidin-2-yl)morpholin-2-yl]benzonitrile Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C=C(C=CC=2)C#N)=NC=1C1=CC=NC=C1 GTZSJDLMBKRWKP-LJQANCHMSA-N 0.000 description 1
- GTZSJDLMBKRWKP-UHFFFAOYSA-N 3-[4-(1-methyl-6-oxo-4-pyridin-4-ylpyrimidin-2-yl)morpholin-2-yl]benzonitrile Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=C(C=CC=2)C#N)=NC=1C1=CC=NC=C1 GTZSJDLMBKRWKP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CZKXICBBJRKGLY-UHFFFAOYSA-N 3-methoxy-4-[4-(1-methyl-6-oxo-4-pyridin-4-ylpyrimidin-2-yl)morpholin-2-yl]benzonitrile Chemical compound COC1=CC(C#N)=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 CZKXICBBJRKGLY-UHFFFAOYSA-N 0.000 description 1
- IARCQHHJOSGXNW-UHFFFAOYSA-N 3-methyl-2-(2-naphthalen-1-ylmorpholin-4-yl)-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C3=CC=CC=C3C=CC=2)=NC=1C1=CC=NC=C1 IARCQHHJOSGXNW-UHFFFAOYSA-N 0.000 description 1
- POGFJQLWAACYFP-UHFFFAOYSA-N 3-methyl-2-(2-naphthalen-2-ylmorpholin-4-yl)-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=C3C=CC=CC3=CC=2)=NC=1C1=CC=NC=C1 POGFJQLWAACYFP-UHFFFAOYSA-N 0.000 description 1
- WQHRSVXKSZGWKC-LJQANCHMSA-N 3-methyl-2-[(2s)-2-(2-methylphenyl)morpholin-4-yl]-6-pyridin-4-ylpyrimidin-4-one Chemical compound CC1=CC=CC=C1[C@@H]1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 WQHRSVXKSZGWKC-LJQANCHMSA-N 0.000 description 1
- POGFJQLWAACYFP-JOCHJYFZSA-N 3-methyl-2-[(2s)-2-naphthalen-2-ylmorpholin-4-yl]-6-pyridin-4-ylpyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2C[C@@H](OCC2)C=2C=C3C=CC=CC3=CC=2)=NC=1C1=CC=NC=C1 POGFJQLWAACYFP-JOCHJYFZSA-N 0.000 description 1
- WQHRSVXKSZGWKC-UHFFFAOYSA-N 3-methyl-2-[2-(2-methylphenyl)morpholin-4-yl]-6-pyridin-4-ylpyrimidin-4-one Chemical compound CC1=CC=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 WQHRSVXKSZGWKC-UHFFFAOYSA-N 0.000 description 1
- MECUTRGCANYVEF-UHFFFAOYSA-N 3-methyl-2-[2-(3-methylphenyl)morpholin-4-yl]-6-pyridin-4-ylpyrimidin-4-one Chemical compound CC1=CC=CC(C2OCCN(C2)C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)=C1 MECUTRGCANYVEF-UHFFFAOYSA-N 0.000 description 1
- RCBCJCXCULVISM-UHFFFAOYSA-N 3-methyl-2-[2-(4-methylphenyl)morpholin-4-yl]-6-pyridin-4-ylpyrimidin-4-one Chemical compound C1=CC(C)=CC=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 RCBCJCXCULVISM-UHFFFAOYSA-N 0.000 description 1
- ANZKPYNLNMNUOY-UHFFFAOYSA-N 3-methyl-6-pyridin-4-yl-2-[2-[2-(trifluoromethoxy)phenyl]morpholin-4-yl]pyrimidin-4-one Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C(=CC=CC=2)OC(F)(F)F)=NC=1C1=CC=NC=C1 ANZKPYNLNMNUOY-UHFFFAOYSA-N 0.000 description 1
- LKWLCDKPCQRWNA-UHFFFAOYSA-N 4-[4-(1-methyl-6-oxo-4-pyridin-4-ylpyrimidin-2-yl)morpholin-2-yl]benzonitrile Chemical compound C=1C(=O)N(C)C(N2CC(OCC2)C=2C=CC(=CC=2)C#N)=NC=1C1=CC=NC=C1 LKWLCDKPCQRWNA-UHFFFAOYSA-N 0.000 description 1
- NAWYNSSXFPEQKE-UHFFFAOYSA-N 4-benzylmorpholine-2-carbonitrile Chemical compound C1COC(C#N)CN1CC1=CC=CC=C1 NAWYNSSXFPEQKE-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- XLURTXXNZBJFDZ-UHFFFAOYSA-N 4-methoxy-3-[4-(1-methyl-6-oxo-4-pyridin-4-ylpyrimidin-2-yl)morpholin-2-yl]benzonitrile Chemical compound COC1=CC=C(C#N)C=C1C1OCCN(C=2N(C(=O)C=C(N=2)C=2C=CN=CC=2)C)C1 XLURTXXNZBJFDZ-UHFFFAOYSA-N 0.000 description 1
- PPQDAVDTHKCDQB-UHFFFAOYSA-N 6-(4-fluorophenyl)-2,2-dimethylmorpholine;hydrochloride Chemical compound Cl.O1C(C)(C)CNCC1C1=CC=C(F)C=C1 PPQDAVDTHKCDQB-UHFFFAOYSA-N 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 230000007466 Aβ secretion Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FZHXIRIBWMQPQF-VANKVMQKSA-N L-glucosamine Chemical compound O=C[C@@H](N)[C@H](O)[C@@H](O)[C@@H](O)CO FZHXIRIBWMQPQF-VANKVMQKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010056332 Panencephalitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- 101001032571 Rattus norvegicus Glycogen synthase kinase-3 beta Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical group C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UMIVXZPTRXBADB-UHFFFAOYSA-N benzocyclobutene Chemical group C1=CC=C2CCC2=C1 UMIVXZPTRXBADB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical group C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940080428 lactose 200 mg Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- QVZZOQYGVUGLSI-UHFFFAOYSA-N n,n-dimethylformamide;formamide Chemical compound NC=O.CN(C)C=O QVZZOQYGVUGLSI-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- CVXGFPPAIUELDV-UHFFFAOYSA-N phenacylazanium;chloride Chemical compound [Cl-].[NH3+]CC(=O)C1=CC=CC=C1 CVXGFPPAIUELDV-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NXYKIFZJQXOUJS-UHFFFAOYSA-N phenyl(piperidin-1-ium-4-yl)methanone;chloride Chemical compound Cl.C=1C=CC=CC=1C(=O)C1CCNCC1 NXYKIFZJQXOUJS-UHFFFAOYSA-N 0.000 description 1
- MNODEQCNDLADAL-UHFFFAOYSA-N phenyl(piperidin-3-yl)methanone;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(=O)C1CCCNC1 MNODEQCNDLADAL-UHFFFAOYSA-N 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical group [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种具有抑制τ蛋白激酶1活性的式(I)代表的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R1代表可被取代的C1-C12烷基;R代表例如右式(II)代表的基团,其中R2和R3独立地代表氢原子或C1-C8烷基;R4代表可被取代的苯环、可被取代的萘环、可被取代的二氢化茚环、可被取代的四氢萘环、或具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环。
Description
本申请是申请号为02818469.6、申请日为2002年9月20日、名称为“3-取代的-4-嘧啶酮衍生物”的专利申请的分案申请。
技术领域
本发明涉及用作药物活性成分以预防和/或治疗主要因τ蛋白激酶1的异常活性引起的疾病,例如神经变性疾病(例如阿耳茨海默氏病)的化合物。
背景技术
阿耳茨海默氏病是进行性的老年性痴呆,其中可观察到由于神经细胞退化和神经细胞数量的减少而导致明显的大脑皮层萎缩。在病理学上,在脑部可见大量的老年斑和神经原纤维缠结。患者的数量已经随着老年人口的增加而增加,并且一系列的社会问题因该病引起。尽管已经提出了很多理论,但是该病的病因仍然没有阐明。尽早辩明病因仍在期待中。
已知阿耳茨海默氏病的两项特征性病理改变的出现程度与智力障碍程度高度相关。因此,从20世纪80年代早期就开始在分子水平上对这两项病理学改变的组分进行调查研究以揭示这种疾病的病因。老年斑在细胞外聚集,并已阐明淀粉样β蛋白是其主要组分(本说明书下文中简称为“Aβ”:Biochem.Biophys.Res.Commun.,120,855(1984);EMBO J.,4,2757(1985);Proc.Natl.Acad.Sci.USA,82,4245(1985))。另一项病理学改变,即,神经原纤维缠结中,称为配对螺旋丝(本说明书下文中简称为“PHF”)的双螺旋丝状物质在细胞内聚集,并且已经发现τ蛋白(脑部特有的一种微管关联蛋白)是其主要组分(Proc.Natl.Acad.Sci.USA,85,4506(1988);Neuron,1,827(1988))。
此外,在基因研究的基础上,发现早老基因(presenilins)1和2是家族性阿耳茨海默氏病的致病基因(自然,375,754(1995);科学,269,973(1995);自然.376.775(1995)),并且已经发现早老基因1和2变种的存在促进Aβ的分泌(Neuron,17,1005(1996);Proc.Natl.Acad.Sci.USA,94,2025(1997))。根据这些结果,一般认为,在阿耳茨海默氏病中,由于某些原因Aβ异常聚集和凝聚,引起PHF的形成进而导致神经细胞死亡。一般还认为谷氨酸流出细胞外以及谷氨酸盐受体对这种外流作出反应而被活化可能是脑血管缺血性意外导致神经细胞死亡的早期阶段中的重要因素(最新医学[Latest Medicine],49,1506(1994))。
已报道卡英酸处理,其刺激AMPA受体,一种谷氨酸盐受体,可增加作为Aβ前体的淀粉样前体蛋白(本说明书下文中简称为“APP”)的mRNA(Society for Neuroscience Abstracts,17,1445(1991)),而且还促进APP代谢(TheJournal of Neuroscience,10,2400(1990))。因此,可以肯定缺血性脑血管疾病所致的细胞死亡与Aβ聚集有关。已经发现Aβ异常聚集和凝聚的其它疾病包括,例如,特瓦(Down)综合症、单纯大脑淀粉样血管病引起的大脑出血、勒尾小体(Lewy body)病(神经进展[Nerve Advance],34,343(1990);蛋白质核酸酶[Protein,Nucleic Acid,Enzyme],41,1476(1996))等。此外,由于PHF聚集而表现出神经原纤维缠结的疾病的实例包括,进行性核上性麻痹、亚急性硬化性全脑炎的帕金森病、脑炎后帕金森病、拳击性脑炎、关岛(Guam)帕金森病-痴呆综合症、勒尾小体病等(蛋白质核酸酶[Protein,Nucleic Acid,Enzyme],36,2(1991);医学进展[Progress of Medicine],158,511(1991);蛋白质核酸酶[Protein,Nucleic Acid,Enzyme],41,1476(1996))。
τ蛋白通常由一组在SDS-聚丙稀酰胺凝胶电泳中形成数条带的分子量为48-65kDa的相关蛋白质组成,而且其促进微管形成。已经证实与通常τ蛋白相比,患有阿耳茨海默氏病的大脑中与PHF结合的τ蛋白被异常磷酸化(J.Biochem.,99,1807(1986);Proc.Natl.Acad.Sci.USA,83,4913(1986))。一种催化该异常磷酸化的酶已经被分离出来。该蛋白质被命名为τ蛋白激酶1(在本说明书下文中简称为“TPK1”),并且其理化性质已经阐明(生物化学[Biochemistry],64,308(1992);J.Biol.Chem.,267,10897(1992))。此外,以TPK1的部分氨基酸序列为基础已经从大鼠大脑皮层cDNA文库中克隆了大鼠TPK1的cDNA,并测定了它的核苷酸序列和推导出氨基酸序列(日本专利未审公开[特开]号6-239893/1994)。其结果是揭示出大鼠TPK1的初始结构与称作大鼠GSK-3β的酶一致(糖原合成酶激酶3β,FEBS Lett.,325,167(1993))。
已报道老年斑的主要组分Aβ具有神经毒性(科学,250,279(1990))。然而,对于Aβ如何导致细胞死亡提出了许多理论,但仍然没有任何一个可靠的理论被确定。Takashima等人发现Aβ处理乳鼠海马原代培养系统引起细胞死亡,并由此发现Aβ处理后TPK1的活性增加以及Aβ所致的细胞死亡被反义TPK1抑制(Proc.Natl.Acad.Sci.USA,90,7789(1993);日本专利未审公开[特开]号6-329551/1994)。
综上所述,抑制TPK1活性的化合物可能能够抑制Aβ的神经毒性以及PHF形成并抑制阿耳茨海默氏病中的神经细胞死亡,因而终止或延缓病情发展。这些化合物还可能被用作药物通过抑制Aβ的神经毒性而治疗缺血性脑血管病、特瓦综合症、大脑淀粉样血管病、勒尾小体病引起的大脑出血等。此外,这些化合物还可能被用作药物而治疗神经变性疾病如进行性核上性麻痹、亚急性硬化性全脑炎的帕金森病、脑炎后帕金森病、拳击性脑炎、关岛帕金森病-痴呆综合症、勒尾小体病、皮克氏病、皮质延髓退化、额颞性痴呆、血管性痴呆、跌打损伤、脑和脊髓外伤、周围神经病、视网膜病和青光眼,以及如下的其它疾病:非胰岛素依赖性糖尿病、肥胖症、躁狂抑郁疾病、精神分裂症、秃发症、乳癌、非小细胞肺癌、甲状腺癌、T或B-细胞白血病和几种病毒诱发的肿瘤。
与后述式(I)代表的本发明化合物结构类似的化合物,下列式(A)代表的化合物是已知的:
其中R代表2,6-二氯苄基、2-(2-氯苯基)乙基氨基、3-苯基丙基氨基或1-甲基-3-苯基丙基氨基(WO98/24782)。式(A)代表的化合物的特征是嘧啶环的5-位上具有4-氟苯基,在4-位上具有一羟基,并且不在本发明的范围内。而且,式(A)代表的化合物的主要药理学活性是抗炎作用,而式(I)代表的本发明化合物是用作TPK1抑制剂或临床治疗神经变性性疾病的药物,因此,它们的药理学活性完全相互不同。
发明内容
本发明所要达到的目的
本发明的目的是提供用作药物活性成分化合物以预防和/或治疗如阿耳茨海默氏病的疾病。更具体地说,其目的是提供用作药物活性成分的新化合物,其通过抑制TPK1活性而抑制Aβ的神经毒性以及PHF形成并通过抑制神经细胞凋亡使之能够从根本上预防和/或治疗如阿耳茨海默氏病的神经变性疾病。
达到该目的的方式
为了达到上述目的,本发明的发明人筛选了具有抑制TPK1磷酸化作用活性的多种化合物。结果,他们发现下式(I)代表的化合物具有所需的活性并可用作预防和/或治疗上述疾病的药物活性成分。本发明是基于这些发现完成的。
因此本发明提供了式(I)代表的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物:
其中R1代表可被取代的C1-C12烷基;
R代表下式(II)-(V)代表的任一基团:
其中R2和R3独立地代表氢原子或C1-C8烷基;
R4代表可被取代的苯环、可被取代的萘环、可被取代的二氢化茚环、可被取代的四氢萘环、或具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环;
R5代表可被取代的C1-C8烷基、可被取代的C3-C8环烷基、可被取代的苯环、可被取代的萘环、可被取代的二氢化茚环、可被取代的四氢萘环或具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环;
R6代表氢原子、可被取代的C1-C8烷基、可被取代的苯环;
或者R5和R6可以彼此结合以与将R5和R6连接的碳一起形成一任选取代的螺碳环,该环总共具有3-11个构成环的原子;
R7和R8独立地代表氢原子或C1-C8烷基,或者R7和R8可以彼此结合形成一C2-C6亚烷基;
R9和R10代表可被取代的C1-C8烷基、可被取代的C3-C8环烷基、可被取代的苯环、可被取代的萘环、具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环,或者R9和R10代表-N(R11)(R12),其中R11代表氢原子、C1-C8烷基;并且R12代表C1-C8烷基、可被取代的苯环、可被取代的萘环、或者具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环;
并且X代表CH2、O或NR13,其中R13代表氢原子或C1-C8烷基。
根据本发明的优选实施方式,提供了:
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R1是甲基;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R是式(II)代表的基团;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R2和R3各自是氢原子;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R是式(III)代表的基团;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R6是氢原子;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R7和R8各自是氢原子;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R7和R8各自是甲基;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R是式(IV)代表的基团;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R9是可被取代的苯环;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中X是CH2;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中X是O;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R是式(V)代表的基团;
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R10是可被取代的苯环;和
前述的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R10是具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的杂环。
根据另一方面,本发明提供了包括以选自前述式(I)代表的嘧啶酮衍生物及其盐、以及其溶剂化物和其水合物作为活性成分的药物,和选自前述式(I)代表的嘧啶酮衍生物及其盐、以及其溶剂化物和其水合物的τ蛋白激酶1抑制剂。
根据前述药物的优选实施方式,提供了前述药物,其用于预防和/或治疗由τ蛋白激酶1活性过高引起的疾病;
前述药物,其用于预防和/或治疗神经变性疾病;
前述药物,其中疾病选自阿耳茨海默氏病、缺血性脑血管意外、特瓦综合症、大脑淀粉样疾病所致的大脑出血、进行性核上性麻痹、亚急性硬化性全脑炎的帕金森病、脑炎后帕金森病、拳击性脑炎、关岛帕金森病-痴呆综合症、勒尾小体病、皮克氏病、皮质延髓退化、额颞性痴呆、血管性痴呆、跌打损伤、脑和脊髓外伤、周围神经病、视网膜病和青光眼,以及
前述药物,其中疾病选自:非胰岛素依赖性糖尿病、肥胖症、躁狂抑郁疾病、精神分裂症、秃发症、乳癌、非小细胞肺癌、甲状腺癌、T或B-细胞白血病、和病毒诱发的肿瘤。
根据本发明的另一方面,提供了一种预防和/或治疗由τ蛋白激酶1活性过高导致的疾病的方法,其步骤包括以有效预防和/或治疗量的选自式(I)的3-取代的-4-嘧啶酮衍生物及其生理学上可接受的盐、及其溶剂化物和其水合物的物质给予患者;以及选自式(I)的3-取代的-4-嘧啶酮衍生物及其生理学上可接受的盐、及其溶剂化物和其水合物的物质在制备前述药物中的用途。
根据本发明的另一方面,提供了式(VI)代表的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物:
其中R1代表可被取代的C1-C12烷基,和式(VII)代表的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物:
其中R1代表可被取代的C1-C12烷基。
具体实施方式
实施本发明的最佳方式
本文中所用的烷基可以是直链或支链的。R1代表的C1-C12烷基可以是,例如,甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基、1,1-二甲基丙基、正己基、异己基、或直链或支链的庚基、辛基、壬基、癸基、十一烷基或十二烷基。在本说明书中,当官能团被定义为“其可被取代”或者“任选取代”时,其取代基的数量及其类型没有特别的限制,并且当存在两个或多个取代基时,它们可以相同或不同。
当R1代表的C1-C12烷基具有一个或一个以上的取代基时,该烷基可以含有一个或一个以上选自如下的取代基:C1-C5烷氧基如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔-丁氧基;氨基、C1-C3烷基氨基或C2-C6二烷基氨基:C6-C10芳基如苯基、1-萘基和2-萘基;
R2或R3代表的C1-C8烷基可以是,例如,甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基、1,1-二甲基丙基、正己基、异己基、或直链或支链的庚基或辛基。
当R4或R5代表的苯环、萘环、二氢化茚环、四氢萘环或杂环具有一个或一个以上的取代基时,这些环可以含有一个或一个以上选自如下的取代基:C1-C5烷基如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、1,1-二甲基丙基;C3-C6环烷基如环丙基、环丁基、环戊基、环己基;C3-C6环烷氧基如环丙氧基、环丁氧基、环戊氧基、环己氧基;C1-C5烷氧基如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔-丁氧基、戊氧基和异戊氧基;C4-C7环烷基烷氧基如环丙基甲氧基、环戊基甲氧基;C1-C5烷硫基如甲硫基、乙硫基、丙硫基、丁硫基和戊硫基;C1-C5烷基磺酰基如甲磺酰基、乙磺酰基、丙磺酰基、丁磺酰基和戊磺酰基;卤原子如氟原子、氯原子、溴原子和碘原子;C1-C5卤代烷基如三氟甲基;C1-C5卤代烷氧基如三氟甲氧基、2,2,2-三氟乙氧基;羟基;氰基;硝基;甲酰基;C2-C6烷基羰基如乙酰基、丙酰基、丁酰基和戊酰基;可被取代的苯环、可被取代的萘环、具有1-4个选自氧原子、硫原子和氮原子的杂原子且具有5-10个构成环的原子的任选取代的杂环、可被取代的苯氧基或可被取代的苯基氨基;氨基;C1-C5一烷基氨基如甲基氨基、乙基氨基、丙基氨基、异丙基氨基、丁基氨基、异丁基氨基、叔丁基氨基、戊基氨基和异戊基氨基;C2-C10二烷基氨基如二甲基氨基、乙基甲基氨基、二乙基氨基、甲基丙基氨基和二异丙基氨基;C2-C10一烷基氨基甲基如甲基氨基甲基、乙基氨基甲基、丙基氨基甲基、异丙基氨基甲基、丁基氨基甲基、异丁基氨基甲基、叔丁基氨基甲基、戊基氨基甲基、异戊基氨基甲基;C3-C11二烷基氨基甲基如二甲基氨基甲基、二乙基氨基甲基、乙基甲基氨基甲基、甲基丙基氨基甲基;吡咯烷基甲基;哌啶子基(piperidinyl)甲基;吗啉代甲基;哌嗪基甲基;吡咯基甲基;咪唑基甲基;吡唑基甲基和三唑基甲基。
当所述苯环、萘环、二氢化茚环、四氢萘环或杂环具有一个或一个以上的取代基时,该取代基还可以具有一个或一个以上选自如下的的取代基:C1-C5烷基如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、1,1-二甲基丙基;C3-C6环烷基如环丙基、环丁基、环戊基、环己基;C3-C6环烷氧基如环丙氧基、环丁氧基、环戊氧基、环己氧基;C1-C5烷氧基如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔-丁氧基、戊氧基和异戊氧基;C4-C7环烷基烷氧基如环丙基甲氧基、环戊基甲氧基;C1-C5烷硫基如甲硫基、乙硫基、丙硫基、丁硫基和戊硫基;C1-C5烷基磺酰基如甲磺酰基、乙磺酰基、丙磺酰基、丁磺酰基和戊磺酰基;卤原子如氟原子、氯原子、溴原子和碘原子;C1-C5卤代烷基如三氟甲基;C1-C5卤代烷氧基如三氟甲氧基、2,2,2-三氟乙氧基;羟基;氰基;硝基;甲酰基;C2-C6烷基羰基如乙酰基、丙酰基、丁酰基和戊酰基;氨基;C1-C5一烷基氨基如甲基氨基、乙基氨基、丙基氨基、异丙基氨基、丁基氨基、异丁基氨基、叔丁基氨基、戊基氨基和异戊基氨基;C2-C10二烷基氨基如二甲基氨基、乙基甲基氨基、二乙基氨基、甲基丙基氨基和二异丙基氨基;C2-C10一烷基氨基甲基如甲基氨基甲基、乙基氨基甲基、丙基氨基甲基、异丙基氨基甲基、丁基氨基甲基、异丁基氨基甲基、叔丁基氨基甲基、戊基氨基甲基、异戊基氨基甲基;C3-C11二烷基氨基甲基如二甲基氨基甲基、二乙基氨基甲基、乙基甲基氨基甲基、甲基丙基氨基甲基等。
R4或R5代表的具有1-4个选自氧原子、硫原子和氮原子的杂原子且具有5-10个构成环的原子的杂环可以是,例如,呋喃环、二氢呋喃环、四氢呋喃环、吡喃环、二氢吡喃环、四氢吡喃环、苯并呋喃环、二氢苯并呋喃、异苯并呋喃环、苯并间二氧杂环戊烯环、色原烯环、色原烷环、异色原烷环、噻吩环、苯并噻吩环、吡咯环、吡咯啉环、吡咯烷环、咪唑环、咪唑啉环、咪唑烷环、吡唑环、吡唑啉环、吡唑烷环、三唑环、四唑环、吡啶环、氧化吡啶环、哌啶环、吡嗪环、哌嗪环、嘧啶环、哒嗪环、吲哚环、二氢吲哚环、异吲哚环、异二氢吲哚环、吲唑环、苯并咪唑环、苯并三唑环、四氢异喹啉环、苯并噻唑啉酮环、苯并唑啉酮环、嘌呤环、喹嗪环、喹啉环、酞嗪环、萘啶环、喹喔啉环、喹唑啉环、噌啉环、蝶啶环、恶唑环、恶唑烷环、异恶唑环、异恶唑烷环、二唑环、噻唑环、苯并噻唑环、噻唑烷环、异噻唑环、异噻唑烷环、苯并二恶茂环、二烷环、苯并二烷环、二噻烷环、吗啉环、硫吗啉环和酞酰亚胺环。
R5、R6、R7或R8代表的C1-C8烷基可以是,例如,甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基、1,1-二甲基丙基、正己基、异己基、或直链或支链的庚基或辛基。
R5代表的C3-C8环烷基可以是,例如,环丙基、环丁基、环戊基、环己基、环庚基或环辛基。
R5代表的C1-C8烷基或C3-C8环烷基,或者R6代表的C1-C8烷基,具有一个或一个以上的取代基,该基团可以具有一个或一个以上选自如下的取代基:卤原子、C1-C6烷氧基、C3-C8环烷基、可被取代的苯环、可被取代的萘环、可被取代的苯氧基或可被取代的苯基氨基;氨基、C1-C6烷基氨基、C2-C12二烷基氨基、1-吡咯烷基、1-哌啶子基(pyperidinyl group)、1-吗啉基、1-(四氢-1,2,3,4-喹啉基)基团或1-(四氢-1,2,3,4-异喹啉基)基团。
当R6代表的苯环具有一个或一个以上的取代基时,该环可以具有一个或一个以上选自如下的取代基:C1-C5烷基如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、1,1-二甲基丙基;C3-C6环烷基如环丙基、环丁基、环戊基、环己基;C3-C6环烷氧基如环丙氧基、环丁氧基、环戊氧基、环己氧基;C1-C5烷氧基如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔-丁氧基、戊氧基和异戊氧基;C4-C7环烷基烷氧基如环丙基甲氧基、环戊基甲氧基;C1-C5烷硫基如甲硫基、乙硫基、丙硫基、丁硫基和戊硫基;C1-C5烷基磺酰基如甲磺酰基、乙磺酰基、丙磺酰基、丁磺酰基和戊磺酰基;卤原子如氟原子、氯原子、溴原子和碘原子;C1-C5卤代烷基如三氟甲基;C1-C5卤代烷氧基如三氟甲氧基、2,2,2-三氟乙氧基;羟基;氰基;硝基;甲酰基;C2-C6烷基羰基如乙酰基、丙酰基、丁酰基和戊酰基;可被取代的苯环、可被取代的萘环、具有1-4个选自氧原子、硫原子和氮原子的杂原子且具有5-10个构成环的原子的任选取代的杂环、可被取代的苯氧基或可被取代的苯基氨基;氨基;C1-C5一烷基氨基如甲基氨基、乙基氨基、丙基氨基、异丙基氨基、丁基氨基、异丁基氨基、叔丁基氨基、戊基氨基和异戊基氨基;C2-C10二烷基氨基如二甲基氨基、乙基甲基氨基、二乙基氨基、甲基丙基氨基和二异丙基氨基;C2-C10一烷基氨基甲基如甲基氨基甲基、乙基氨基甲基、丙基氨基甲基、异丙基氨基甲基、丁基氨基甲基、异丁基氨基甲基、叔丁基氨基甲基、戊基氨基甲基、异戊基氨基甲基;C3-C11二烷基氨基甲基如二甲基氨基甲基、二乙基氨基甲基、乙基甲基氨基甲基、甲基丙基氨基甲基;吡咯烷基甲基;哌啶基(pipelidinyl)甲基;吗啉代甲基;哌嗪基甲基;吡咯基甲基;咪唑基甲基;吡唑基甲基;三唑基甲基。
当R6代表的苯环具有一个或一个以上的取代基时,该取代基还可以具有一个或一个以上选自如下的取代基:C1-C5烷基如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、1,1-二甲基丙基;C3-C6环烷基如环丙基、环丁基、环戊基、环己基;C3-C6环烷氧基如环丙氧基、环丁氧基、环戊氧基、环己氧基;C1-C5烷氧基如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔-丁氧基、戊氧基和异戊氧基;C4-C7环烷基烷氧基如环丙基甲氧基、环戊基甲氧基;C1-C5烷硫基如甲硫基、乙硫基、丙硫基、丁硫基和戊硫基;C1-C5烷基磺酰基如甲磺酰基、乙磺酰基、丙磺酰基、丁磺酰基和戊磺酰基;卤原子如氟原子、氯原子、溴原子和碘原子;C1-C5卤代烷基如三氟甲基;C1-C5卤代烷氧基如三氟甲氧基、2,2,2-三氟乙氧基;羟基;氰基;硝基;甲酰基;C2-C6烷基羰基如乙酰基、丙酰基、丁酰基和戊酰基;氨基;C1-C5一烷基氨基如甲基氨基、乙基氨基、丙基氨基、异丙基氨基、丁基氨基、异丁基氨基、叔丁基氨基、戊基氨基和异戊基氨基;C2-C10二烷基氨基如二甲基氨基、乙基甲基氨基、二乙基氨基、甲基丙基氨基和二异丙基氨基;C2-C10一烷基氨基甲基如甲基氨基甲基、乙基氨基甲基、丙基氨基甲基、异丙基氨基甲基、丁基氨基甲基、异丁基氨基甲基、叔丁基氨基甲基、戊基氨基甲基、异戊基氨基甲基;C3-C11二烷基氨基甲基如二甲基氨基甲基、二乙基氨基甲基、乙基甲基氨基甲基、甲基丙基氨基甲基。
当R5和R6彼此结合与R5和R6相连的碳原子一起形成以螺碳环时,该碳环可以是,例如,环丙基环、环丁基环、环戊基环、环己基环、环庚基环、四氢苯并环庚烯环、四氢萘环、二氢化茚环、双环[4,2,0]辛-1,3,5-三烯环。
R9、R10、R11、R12或R13代表的C1-C8烷基可以是,例如,甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基、1,1-二甲基丙基、正己基、异己基、或直链或支链的庚基或辛基。
R9或R10代表的C3-C8环烷基可以是,例如,环丙基、环丁基、环戊基、环己基、环庚基或环辛基。
当R9或R10代表的C1-C8烷基或C3-C8环烷基具有一个或一个以上的取代基时,该基团可以具有一个或一个以上选自如下的取代基:卤原子、C3-C8环烷基、可被取代的苯环、可被取代的萘环、具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环。
当R9或R10代表的苯环、萘环或杂环具有一个或一个以上的取代基时,该环可以具有一个或一个以上选自如下的取代基:C1-C5烷基如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、1,1-二甲基丙基;C3-C6环烷基如环丙基、环丁基、环戊基、环己基;C3-C6环烷氧基如环丙氧基、环丁氧基、环戊氧基、环己氧基;C1-C5烷氧基如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔-丁氧基、戊氧基和异戊氧基;C4-C7环烷基烷氧基如环丙基甲氧基、环戊基甲氧基;C1-C5烷硫基如甲硫基、乙硫基、丙硫基、丁硫基和戊硫基;C1-C5烷基磺酰基如甲磺酰基、乙磺酰基、丙磺酰基、丁磺酰基和戊磺酰基;卤原子如氟原子、氯原子、溴原子和碘原子;C1-C5卤代烷基如三氟甲基;C1-C5卤代烷氧基如三氟甲氧基、2,2,2-三氟乙氧基;羟基;氰基;硝基;甲酰基;C2-C6烷基羰基如乙酰基、丙酰基、丁酰基和戊酰基;可被取代的苯环、可被取代的萘环、具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环;可被取代的苯氧基;可被取代的苯基氨基;氨基;C1-C5一烷基氨基如甲基氨基、乙基氨基、丙基氨基、异丙基氨基、丁基氨基、异丁基氨基、叔丁基氨基、戊基氨基和异戊基氨基;C2-C10二烷基氨基如二甲基氨基、乙基甲基氨基、二乙基氨基、甲基丙基氨基和二异丙基氨基;C1-C5一烷基氨基甲基如甲基氨基甲基、乙基氨基甲基、丙基氨基甲基、异丙基氨基甲基、丁基氨基甲基、异丁基氨基甲基、叔丁基氨基甲基、戊基氨基甲基、异戊基氨基甲基;C2-C10二烷基氨基甲基如二甲基氨基甲基、二乙基氨基甲基、乙基甲基氨基甲基、甲基丙基氨基甲基;吡咯烷基甲基;哌啶子基甲基;吗啉代甲基;哌嗪基甲基;吡咯基甲基;咪唑基甲基;吡唑基甲基和三唑基甲基。
R9或R10代表的具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的杂环杂环可以是,例如,呋喃环、二氢呋喃环、四氢呋喃环、吡喃环、二氢吡喃环、四氢吡喃环、苯并呋喃环、二氢苯并呋喃、异苯并呋喃环、苯并间二氧杂环戊烯环、色原烯环、色原烷环、异色原烷环、噻吩环、苯并噻吩环、吡咯环、吡咯啉环、吡咯烷环、咪唑环、咪唑啉环、咪唑烷环、吡唑环、吡唑啉环、吡唑烷环、三唑环、四唑环、吡啶环、氧化吡啶环、哌啶环、吡嗪环、哌嗪环、嘧啶环、哒嗪环、吲哚环、二氢吲哚环、异吲哚环、异二氢吲哚环、吲唑环、苯并咪唑环、苯并三唑环、四氢异喹啉环、苯并噻唑啉酮环、苯并唑啉酮环、嘌呤环、喹嗪环、喹啉环、酞嗪环、萘啶环、喹喔啉环、喹唑啉环、噌啉环、蝶啶环、恶唑环、恶唑烷环、异恶唑环、异恶唑烷环、二唑环、噻唑环、苯并噻唑环、噻唑烷环、异噻唑环、异噻唑烷环、苯并二恶茂环、二烷环、苯并二烷环、二噻烷环、吗啉环、硫吗啉环或酞酰亚胺环。
当R12代表的苯环、萘环或杂环具有一个或一个以上的取代基时,该环可以被一个或一个以上选自如下的取代基取代:卤原子、C1-C5烷基、C3-C6环烷基、C3-C6环烷氧基、C1-C5烷氧基、C4-C7环烷基烷氧基、C1-C5烷硫基、C1-C5烷基磺酰基、C1-C5卤代烷基和苯环。
当该苯环、萘环或杂环具有一个或一个以上的取代基时,该取代基还可以具有一个或一个以上选自如下的取代基:C1-C5烷基如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、异戊基、新戊基、1,1-二甲基丙基;C3-C6环烷基如环丙基、环丁基、环戊基、环己基;C3-C6环烷氧基如环丙氧基、环丁氧基、环戊氧基、环己氧基;C1-C5烷氧基如甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔-丁氧基、戊氧基和异戊氧基;C4-C7环烷基烷氧基如环丙基甲氧基、环戊基甲氧基;C1-C5烷硫基如甲硫基、乙硫基、丙硫基、丁硫基和戊硫基;C1-C5烷基磺酰基如甲磺酰基、乙磺酰基、丙磺酰基、丁磺酰基和戊磺酰基;卤原子如氟原子、氯原子、溴原子和碘原子;C1-C5卤代烷基如三氟甲基;C1-C5卤代烷氧基如三氟甲氧基、2,2,2-三氟乙氧基;羟基;氰基;硝基;甲酰基;C2-C6烷基羰基如乙酰基、丙酰基、丁酰基、和戊酰基;氨基;C1-C5一烷基氨基如甲基氨基、乙基氨基、丙基氨基、异丙基氨基、丁基氨基、异丁基氨基、叔丁基氨基、戊基氨基和异戊基氨基;C2-C10二烷基氨基如二甲基氨基、乙基甲基氨基、二乙基氨基、甲基丙基氨基和二异丙基氨基;C2-C10一烷基氨基甲基如甲基氨基甲基、乙基氨基甲基、丙基氨基甲基、异丙基氨基甲基、丁基氨基甲基、异丁基氨基甲基、叔丁基氨基甲基、戊基氨基甲基、异戊基氨基甲基;C3-C11二烷基氨基甲基如二甲基氨基甲基、二乙基氨基甲基、乙基甲基氨基甲基、甲基丙基氨基甲基等。
R1可以优选是C1-C3烷基,更优选是甲基。
R2可以优选是氢原子。
R3可以优选是氢原子。
R4可以优选是可被取代的苯环。
R5可以优选是可被取代的苯环或萘环。
R6可以优选是氢原子。
R7和R8可以优选是氢原子或C1-C3烷基。
R9或R10可以优选是可被取代的苯环。
R10可以优选是具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的可被取代的杂环。特别优选的R10是可被取代的苯环、可被取代的2,3-二氢吲哚环、或可被取代的3,4-二氢-2H-喹啉环。
特别优选的X是CH2或O。
前述式(I)代表的化合物可以成盐。这些盐的实例包括,当存在酸性基团时,与碱金属和碱土金属如锂、钠、钾、镁和钙所成的盐;与铵和胺如甲胺、二甲胺、三甲胺、二环己胺、三(羟基甲基)氨基甲烷、N,N-双(羟基乙基)哌嗪、2-氨基-2-甲基-1-丙醇、乙醇胺、N-甲基葡糖胺和L-葡糖胺所成的盐;或与碱性氨基酸如赖氨酸、8-羟基赖氨酸和精氨酸所成的盐。当存在碱性基团时,实例包括与无机酸如盐酸、氢溴酸、硫酸、硝酸和磷酸所成的盐,与有机酸如甲磺酸、苯磺酸、对-甲苯磺酸、乙酸、丙酸、酒石酸、富马酸、马来酸、苹果酸、草酸、琥珀酸、柠檬酸、苯甲酸、偏桃酸、肉桂酸、乳酸、羟基乙酸、葡糖醛酸、抗坏血酸、烟酸和水杨酸所成的盐;或与酸性氨基酸如天冬氨酸和谷氨酸所成的盐。
除前述式(I)代表的3-取代的-4-嘧啶酮衍生物及其盐之外,它们的溶剂化物和水合物也在本发明的范围之内。前述式(I)代表的3-取代的-4-嘧啶酮衍生物可以具有一个或一个以上的不对称碳原子。对于这些不对称碳原子的立体化学,它们可以独立地为(R)或(S)构型,而该嘧啶酮衍生物可以存在立体异构体如旋光异构体或非对映异构体。任何纯净形式的立体异构体、任何立体异构体的混合物、外消旋体等,都在本发明的范围之内。
优选的本发明化合物的实例如下表所示。然而,本发明的范围不受下列化合物的限制。
化合物B288和B289
·测定条件
CHIRALPAK AD
流动相:正己烷∶异丙醇=80∶20
流速:1.0ml/min
温度:30℃
·保留时间
B288:18.1min
B289:18.6min
化合物C389和C390
·测定条件
CHIRALPAK AD
流动相:正己烷∶异丙醇=60∶40
流速:1.0ml/min
温度:30℃
·保留时间
C389:12.0min
C390:14.7min
式(I)代表的本发明的特别优选的化合物包括:
3-甲基-2-(2-氧杂-2-苯基乙基氨基)-6-吡啶-4-基-3H-嘧啶-4-酮;
3-甲基-2-(2-氧杂-2-(3-氟苯基)乙基氨基)-6-吡啶-4-基-3H-嘧啶-4-酮;
3-甲基-2-(2-氧杂-2-(4-氟苯基)乙基氨基)-6-吡啶-4-基-3H-嘧啶-4-酮;
3-甲基-2-(2-氧杂-2-(3-氯苯基)乙基氨基)-6-吡啶-4-基-3H-嘧啶-4-酮;
3-甲基-2-(2-氧杂-2-(3-甲基苯基)乙基氨基)-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(4-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氯苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(3-氯苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-氯苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2-氯苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-溴苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(4-溴苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(3-溴苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(3-溴苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-溴苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-甲基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(3-甲基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-甲基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2-甲基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氰基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(3-氰基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(3-氰基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-氰基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(4-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(3-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(3-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-乙氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-三氟甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(5-氟-2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氟-2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(4-氟-2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,5-二甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,5-二甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-氯-4,5-二氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2-氯-4,5-二氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-溴-4-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,4-二氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,4-二氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,6-二甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,6-二甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,4-二甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,4-二甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,6-二氯苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,6-二氯苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,6-二氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,6-二氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-氯-6-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2-氯-6-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氟-3-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(5-氰基-2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(5-氰基-2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氰基-2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(4-氰基-2-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,4-二氟-6-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,4-二氟-6-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-(吡咯烷-1-基-甲基)苯基)吗啉代-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(4-(吡咯烷-1-基-甲基)苯基)吗啉代-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(1-萘基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-萘基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2-萘基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2,3-二氢苯并呋喃-7-基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(2,3-二氢苯并呋喃-7-基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(苯并呋喃-2-基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
(S)-2-[2-(苯并呋喃-2-基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[3-(4-氟苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-(3-苯甲酰基哌啶-1-基)-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[3-(2-甲氧基苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[3-(4-甲氧基苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氟苯甲酰基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-(2-苯甲酰基吗啉-4-基)-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-甲氧基苯甲酰基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-甲氧基苯甲酰基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[4-(4-氯苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[4-(3,4-二氢-2H-喹啉-1-羰基)-哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;和
2-[4-(2,3-二氢吲哚-1-羰基)-哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮。
前述优选化合物的盐、和前述化合物及其盐的溶剂化物或水合物也为优选。
前述式(I)代表的3-取代的-4-嘧啶酮化合物,其中R是式(II)代表的基团,可以按照,例如,下面描述的方法制备。
(上面流程中,R1、R2、R3和R4的定义与已经描述的那些相同。)
上面的式(XI)代表的2-硫嘧啶酮是通过EP 354,179中所述的方法的改进容易地制得的。该反应在有碱如氢氧化钠、氢氧化钾、甲氧基钠、乙氧基钠、叔丁氧基钾、碳酸钠、碳酸氢钠、碳酸钾、三乙胺、二异丙基乙基胺和1,8-二氮杂双环[5,4,0]十一碳-7-烯的情况下在从0℃到200℃范围内的适宜温度下,在氮气和氩气环境或者普通空气中进行1-100小时,得到所需化合物(XI)。该反应用的溶剂的实例包括,例如,醇溶剂如甲醇、乙醇、1-丙醇、异丙醇、叔-丁醇、乙二醇、丙二醇;醚溶剂如二乙醚、叔丁基甲基醚、四氢呋喃、异丙基醚;烃溶剂如苯、甲苯、二甲苯;卤代烃溶剂如二氯甲烷、氯仿、二氯乙烷;非质子极性溶剂如甲酰胺、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲亚砜、环丁砜、六甲基磷酸三胺、水等。通常,可以采用单一溶剂或两种和两种以上的溶剂混合物以适合所采用的碱。
然后通过氯化剂将2-硫嘧啶酮衍生物(XI)转变成2-氯嘧啶酮(XII)。其反应时间和温度取决于所用的氯化剂。用于这些反应的氯化剂的实例包括,例如,亚硫酰氯、亚硫酰氯和二甲基甲酰胺、磷酰氯、磷酰氯和二甲基甲酰胺、草酰氯、亚磷酰氯和二甲基甲酰胺、五氯化磷。
上面的式(XIII)代表的胺或其盐可以通过文献(Tetrahedron Lett.,30,5285(1989),Synthesis,122(1990))中所述的方法的改进制得。
然后将该氯化物衍生物(XII)与胺(XIII)或其盐在有碱如氢氧化钠、氢氧化钾、甲氧基钠、乙氧基钠、碳酸钠、碳酸氢钠、碳酸钾、三乙胺、二异丙基乙基胺和1,8-二氮杂双环[5,4,0]十一碳-7-烯的情况下在从0℃到200℃范围内的适宜温度下,在氮气和氩气环境或者普通空气中进行1-100小时,得到所需化合物(I)。可以使用4-二甲基氨基吡啶作为催化剂。
用于该反应的溶剂的实例包括,例如,醇溶剂如甲醇、乙醇、1-丙醇、异丙醇、叔-丁醇、乙二醇、丙二醇;醚溶剂如二乙醚、叔丁基甲基醚、四氢呋喃、异丙基醚;烃溶剂如苯、甲苯、二甲苯;卤代烃溶剂如二氯甲烷、氯仿、二氯乙烷;非质子极性溶剂如甲酰胺、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲亚砜、环丁砜、六甲基磷酸三胺、水等。通常,可以采用单一溶剂或两种和两种以上的溶剂混合物以适合所采用的碱。
前述式(I)代表的3-取代的-4-嘧啶酮化合物,其中R是式(III)代表的基团,可以按照,例如,下面描述的方法制备。
(上面流程中,R1、R5、R6、R7和R8的定义与已经描述的那些相同。)
使氯化物衍生物(XII)与胺(IVX)或其盐在有碱如氢氧化钠、氢氧化钾、甲氧基钠、乙氧基钠、碳酸钠、碳酸氢钠、碳酸钾、三乙胺、二异丙基乙基胺和1,8-二氮杂双环[5,4,0]十一碳-7-烯的情况下在从0℃到200℃范围内的适宜温度下,在氮气和氩气环境或者普通空气中进行1-100小时,得到所需化合物(I)。
用于该反应的溶剂的实例包括,例如,醇溶剂如甲醇、乙醇、1-丙醇、异丙醇、叔-丁醇、乙二醇、丙二醇;醚溶剂如二乙醚、叔丁基甲基醚、四氢呋喃、异丙基醚;烃溶剂如苯、甲苯、二甲苯;卤代烃溶剂如二氯甲烷、氯仿、二氯乙烷;非质子极性溶剂如甲酰胺、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲亚砜、环丁砜、六甲基磷酸三胺、水等。通常,可以采用单一溶剂或两种和两种以上的溶剂混合物以适合所采用的碱。
前述式(I)代表的3-取代的-4-嘧啶酮化合物,其中R是式(IV)代表的基团,可以按照,例如,下面描述的方法制备。
(上面流程中,R1、R9和X的定义与已经描述的那些相同。)
上面式(VX)代表的胺可以通过文献(J.Med.Chem.,13,1(1970),J.Med.Chem.,41,591(1998))中所述的方法的改进或者按照本领域技术人员公知的方法制得。
然后将该氯化物衍生物(XII)与胺(VX)或其盐在有碱如氢氧化钠、氢氧化钾、甲氧基钠、乙氧基钠、碳酸钠、碳酸氢钠、碳酸钾、三乙胺、二异丙基乙基胺和1,8-二氮杂双环[5,4,0]十一碳-7-烯的情况下在从0℃到200℃范围内的适宜温度下,在氮气和氩气环境或者普通空气中进行1-100小时,得到所需化合物(I)。
用于该反应的溶剂的实例包括,例如,醇溶剂如甲醇、乙醇、1-丙醇、异丙醇、叔-丁醇、乙二醇、丙二醇;醚溶剂如二乙醚、叔丁基甲基醚、四氢呋喃、异丙基醚;烃溶剂如苯、甲苯、二甲苯;卤代烃溶剂如二氯甲烷、氯仿、二氯乙烷;非质子极性溶剂如甲酰胺、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲亚砜、环丁砜、六甲基磷酸三胺、水等。通常,可以采用单一溶剂或两种和两种以上的溶剂混合物以适合所采用的碱。
前述式(I)代表的3-取代的-4-嘧啶酮化合物,其中R是式(V)代表的基团,可以按照,例如,下面描述的方法制备。
(上面流程中,R1和R10的定义与已经描述的那些相同。)
上面式(VIX)代表的胺可以商购获得或者可以通过文献(J.Med.Chem.,13,1(1970),J.Med.Chem.,41,591(1998))中所述的方法的改进或者按照本领域技术人员公知的方法制得。
然后将该氯化衍生物(XII)与胺(VIX)或其盐在有碱如氢氧化钠、氢氧化钾、甲氧基钠、乙氧基钠、碳酸钠、碳酸氢钠、碳酸钾、三乙胺、二异丙基乙基胺和1,8-二氮杂双环[5,4,0]十一碳-7-烯的情况下在从0℃到200℃范围内的适宜温度下,在氮气和氩气环境或者普通空气中进行1-100小时,得到所需化合物(I)。
用于该反应的溶剂的实例包括,例如,醇溶剂如甲醇、乙醇、1-丙醇、异丙醇、叔-丁醇、乙二醇、丙二醇;醚溶剂如二乙醚、叔丁基甲基醚、四氢呋喃、异丙基醚;烃溶剂如苯、甲苯、二甲苯;卤代烃溶剂如二氯甲烷、氯仿、二氯乙烷;非质子极性溶剂如甲酰胺、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N-甲基吡咯烷酮、二甲亚砜、环丁砜、六甲基磷酸三胺、水等。通常,可以采用单一溶剂或两种和两种以上的溶剂混合物以适合所采用的碱。
本发明化合物具有抑制TPK1的活性、而且它们在神经变性疾病如阿耳茨海默氏病中抑制TPK1的活性,因此可抑制Aβ的神经毒性和PHF的形成以及抑制神经细胞死亡。相应地,本发明化合物被用作药物的活性成分使之能够从根本上预防和/或治疗阿耳茨海默氏病。此外,本发明化合物还可以用作药物的活性成分以预防和/或治疗缺血性脑血管意外、特瓦综合症、单纯大脑淀粉样血管病引起的大脑出血、进行性核上性麻痹、亚急性硬化性全脑炎、脑炎后帕金森病、拳击性脑炎、关岛帕金森病-痴呆综合症、勒尾小体病、皮克氏病、皮质变性额颞性痴呆、血管性痴呆、跌打损伤、脑和脊髓外伤、周围神经病、视网膜病和青光眼、非胰岛素依赖性糖尿病、肥胖症、躁狂抑郁疾病、精神分裂症、秃发症、乳癌、非小细胞肺癌、甲状腺癌、T或B-细胞白血病、和几种病毒诱发的肿瘤。
至于本发明药物的活性成分,其可以采用的物质选自一组包括前述式(I)代表的化合物及其药理学上可接受的盐、以及它们的溶剂化物和它们的水合物。该物质本身可以作为本发明的药物给药,然而通常希望以药物组合物形式的药物给药,其包括作为活性成分的上述物质以及一种或一种以上的药用添加剂。至于本发明药物的活性成分,可以将两种或者两种以上的上述物质联合使用。上述药用组合物可以补充用于治疗阿耳茨海默氏病和上述疾病的其它药物活性成分。
药用组合物的类型没有特别限制,并且可以提供任何适合口服或胃肠外给药的该组合物制剂。例如,药用组合物可以配制成,例如,适合口服的药用组合物剂型如颗粒剂、精细颗粒、粉剂、硬胶囊、软胶囊、糖浆剂、乳剂、混悬液、溶液等,或以适合胃肠外给药的药用剂型如适合静脉内、肌肉内或皮下给药的注射剂,滴注制剂、透皮制剂、透粘膜制剂、滴鼻剂、吸入剂、栓剂等。注射剂或滴注制剂可以制备成粉末状的制剂如冷冻干燥剂型,并且可以在使用之前溶解在合适的含水介质如生理盐水中。延缓释放制剂如用聚合物包衣的那些可以大脑内直接给药。
用于制备药用组合物的药用添加剂种类、相对于活性成分的药用添加剂的含有率,以及药用组合物的制备方法可以由本领域技术人员适当地选择。无机或有机物质,或者固体或液体物质可以用作药用添加剂。通常,以活性成分重量计,掺入的药用添加剂的重量比范围为1%-90%。
用于制备固体药用组合物的赋形剂包括,例如,乳糖、蔗糖、淀粉、滑石粉、纤维素、糊精、高岭土、碳酸钙等。对于口服液体组合物制剂,可以采用常规的惰性稀释剂如水或植物油。除惰性稀释剂之外,液体组合物还可以含有辅料如润湿剂、助悬剂、甜味剂、芳香剂、着色剂和防腐剂。该液体组合物可以填充到由可吸收材料如明胶制成的胶囊中。用作胃肠外给药的组合物制剂,例如,注射剂、栓剂的溶剂或悬液介质的实例包括水、丙二醇、聚乙二醇、苯甲醇、油酸乙酯、卵磷脂等。用作栓剂基质材料的实例包括,例如,可可脂、乳化可可脂、月桂脂、维特普溶胶(witepsol)。
本发明药物的给药剂量和次数没有特别的限制,并且它们可以根据情况如预防和/或治疗的目的、疾病类型、患者的体重或年龄、疾病严重程度等而适当地选择。通常,成人口服每日剂量可以为0.01-1,000mg(活性成分的重量),并且可以每天给药一次或者每天以分剂量给药数次,或者数天给药一次。当采用药物的注射剂时,对成人给药可优选按每天0.001-100mg(活性成分的重量)的剂量连续或者间断地进行给药。
实施例
本发明将参照实施例作更详细的说明。然而,本发明的范围不受下列实施例的限制。实施例中的化合物编号与上述表格相对应。
实施例1:2-巯基-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮的合成
将3-氧杂-3-(4-吡啶基)丙酸乙酯(29.0g,150mmol)、N-甲基硫脲(40.6g,450mmol)和1,8-二氮杂双环[5,4,0]-7-十一碳烯(22.4ml,150mmol)的溶液回流4小时并在用冰水冷却之后加入甲磺酸(14.4g,150mmol)的水(50ml)溶液。用水洗涤该沉淀物,过滤并干燥,得到标题化合物(23.7g,72%)。
1H-NMR(DMSO-d6)δ:3.58(s,3H),6.40(s,1H),7.72(dd,J=1.8,4.5Hz,2H),8.73(dd,J=1.5,4.8Hz,2H),12.92(brd,1H)。
实施例2:2-氯-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮的合成
将磷酰氯(26.11g,170mmol)加入到二甲基甲酰胺(180ml)中并搅拌20分钟。向该溶液中加入2-巯基-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(24.15g,110mmol)并搅拌5分钟,然后在70℃下搅拌2小时。向该冰冷溶液中加入乙酸乙酯(630ml)并在搅拌20分钟之后过滤收集沉淀物。干燥之后,将该沉淀物溶解在水(400ml)中并用氢氧化钠水溶液将pH值调整至10。沉淀物用水洗涤,过滤并干燥,得到标题化合物(18.82g,77%)。
1H-NMR(CDCl3)δ:3.72(s,3H),6.90(s,1H),7.78(dd,J=1.7,4.5Hz,2H),8.75(dd,J=1.6,4.5Hz,2H)。
实施例3:3-甲基-2-(2-氧杂-2-苯基乙基氨基)-6-吡啶-4-基-3H-嘧啶-4-酮(表-1中的化合物编号A001)的合成
将2-氨基-1-苯基-乙酮盐酸盐(1.03g,6.00mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(0.665g,3.00mmol)、4-二甲基氨基吡啶(36.0mg,0.30mmol)和三乙胺(0.80ml,6.00mmol)的二甲亚砜(15ml)溶液于室温下搅拌。搅拌几小时之后,向该反应混合物中加入水。过滤出沉淀物并用回流的二乙醚洗涤,得到标题化合物(0.556g,68%)。
1H-NMR(CDCl3)δ:3.41(s,3H),4.90(d,J=5.1Hz,2H),6.46(s,1H),7.50-7.65(m,2H),7.67-7.80(m,3H),7.90(t,J=5.1Hz,1H),8.08(m,2H),8.47(dd,J=1.5Hz,4.8Hz,2H)。
MS[M+H]+:321。
实施例4:(S)-2-[2-(4-甲氧基苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮(表-1中的化合物编号B079)的合成
将(S)-2-(4-甲氧基苯基)吗啉盐酸盐(1.02g,4.44mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(0.76g,3.42mmol)和三乙胺(1.42ml,10.3mmol)的四氢呋喃(20ml)溶液回流几小时,冷却之后过滤出沉淀物并在真空下除去溶剂。将残余物用回流的二乙醚洗涤,得到标题化合物(1.22g,95%)。
1H-NMR(DMSO-d6)δ:2.98-3.06(m,1H),3.15-3.22(m,1H),3.47(s,3H),3.69-3.73(m,2H),3.76(s,3H),3.85-3.92(m,1H),4.04-4.08(m,1H),4.67-4.70(m,1H),6.95(d,J=8.5Hz,2H),7.10(s,1H),7.38(d,J=8.5Hz,2H),8.49(d,J=6.0Hz,2H),8.94(d,J=6.0Hz,2H)。
MS[M+H]+:379。
实施例5:2-[2,2-二甲基-6-(4-氟苯基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮(表-1中的化合物编号B214)的合成
将2,2-二甲基-6-(4-氟苯基)吗啉盐酸盐(127mg,0.517mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(109mg,0.491mmol)和三乙胺(0.180ml,1.29mmol)的N,N-二甲基甲酰胺(2ml)溶液于室温下搅拌。搅拌几小时之后,向该反应混合物中加入水。过滤出沉淀物,用水洗涤并干燥,得到标题化合物(166mg,81%)。
1H-NMR(CDCl3)δ:1.39(s,3H),1.51(s,3H),2.86-3.02(m,2H),3.39(m,1H),3.60(s,3H),3.65(m,1H),5.04(m,1H),6.69(s,1H),7.09(m,2H),7.42(m,2H),7.79(d,J=6.0Hz,2H),8.72(d,J=6.0Hz,2H)。
MS[M+H]+:394。
实施例6:2-(3-苯甲酰基哌啶-1-基)-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮(表-1中化合物编号C001)的合成
将3-苯甲酰基哌啶盐酸盐(109mg,0.60mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(118mg,0.40mmol)和三乙胺(0.50ml,4.00mmol)的四氢呋喃(6ml)溶液于室温下搅拌几小时。将该反应混合物倒入水中并用乙酸乙酯萃取。有机层用盐水洗涤,在Na2SO4上干燥并在真空下蒸发。通过硅胶柱色谱法(乙酸乙酯)将残余物纯化,得到标题化合物(182mg,61%)。
实施例7:1-(1-甲基-6-氧杂-4-吡啶-4-基-1,6-二氢-嘧啶-2-基)-哌啶-3-羧基苯胺(表-1中化合物编号C067)的合成
将1-叔丁氧基羰基-3-哌啶羧酸(458mg,2.00mmol)、氢化钠(88mg,2.20mmol,60%油悬液)、草酰氯(0.22ml,2.50mmol)和催化量的二甲基甲酰胺(0.20ml)的二氯甲烷(16ml)溶液于0℃下搅拌。搅拌30分钟之后,在0℃下向该反应混合物中加入用正丁基锂(1.45ml,2.30mmol,1.59M于甲烷中)的四氢呋喃(4ml)处理过的苯胺(0.20ml,2.20mmol)。另外搅拌30分钟之后,加入饱和氯化铵并将整个反应混合物用乙酸乙酯萃取。有机相用盐水洗涤,并在Na2SO4上干燥,在真空下蒸发。残余物通过硅胶柱色谱法(己烷-乙酸乙酯)纯化,得到1-叔丁氧基羰基哌啶-3-羧基苯胺(437mg,71%)。
将1-叔丁氧基羰基-3-哌啶羧基苯胺(437mg,1.43mmol)和盐酸(1ml,4.00mmol,4N乙酸乙酯)的溶液搅拌几小时。过滤出沉淀物,得到3-哌啶羧基苯胺盐酸盐(187mg,55%)。
将3-哌啶羧基苯胺盐酸盐(96.0mg,0.40mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(66.0mg,0.30mmol)和三乙胺(0.33ml,2.50mmol)的四氢呋喃(3ml)溶液于室温下搅拌3小时。整个反应混合物于真空下蒸发并将残余物用水和二乙醚洗涤,得到标题化合物(107mg,92%)。
实施例8:2-(2-苯甲酰基吗啉-4-基)-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮(表-1中化合物编号C101)的合成
通过将镁(932mg,5.93mmol)与溴苯(144mg,5.93mmol)在二乙醚(20ml)中于室温下反应10分钟制备格里尼亚氏试剂。冷却至0℃之后,加入2-氰基-4-苄基-吗啉(1.00g,4.94mmol)的二乙醚(2.0ml)溶液,然后加入四氢呋喃(6.0ml)。在室温下将该混合物搅拌30分钟。用饱和碳酸氢钠水溶液分解之后,将混合物过滤并在减压下浓缩。粗产物通过快速色谱法在硅胶(正己烷-乙酸乙酯3∶1至2∶1)纯化,得到该2-苯甲酰基-4-苄基吗啉(608mg,44%)。
(CDCl3):2.20-2.40(m,2H),2.60-2.80(m,1H),3.00-3.20(m,1H),3.55(dd,J=13.0,27.8Hz,2H),3.70-3.90(m,1H),3.90-4.20(m,1H),4.92(dd,J=2.6,9.9Hz,1H),7.20-7.60(m,8H),7.80-8.00(m,2H)。
将2-苯甲酰基-4-苄基吗啉(600mg,2.13mmol)和氯甲酸1-氯甲酯(457mg,3.20mmol)的1,2-二氯乙烷(8.0ml)溶液回流1小时。在减压下将反应混合物浓缩。将残余物溶解在甲醇(10ml)中。将该溶液回流1小时并在减压下浓缩。粗产物从乙酸乙酯中结晶并过滤,得到2-苯甲酰基吗啉盐酸盐(323mg,67%)无色结晶。
(DMSO-d6):3.00-3.50(m,4H),4.00-4.20(m,2H),5.29(dd,J=2.6,10.1Hz,1H),7.50-8.10(m,5H),9.40-9.90(brd,2H)。
将2-苯甲酰基吗啉盐酸盐(269mg,1.17mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(320mg,1.41mmol)和三乙胺(0.49ml,3.51mmol)的四氢呋喃(10ml)溶液回流几小时。冷却之后过滤出沉淀物并在真空下除去溶剂。残余物用回流的乙酸乙酯和二乙醚洗涤,得到标题化合物(447mg,重量)。
实施例9:2-(4-苯甲酰基哌啶-1-基)-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮(表-1中化合物编号D001)的合成
将4-苯甲酰基哌啶盐酸盐(903mg,4.00mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(666mg,3.00mmol)和三乙胺(2.0ml,15mmol)的四氢呋喃(30ml)溶液回流几小时。冷却之后,向该反应混合物中加入水。过滤出沉淀物,用水洗涤并干燥,得到标题化合物(1.00g,81%)。
实施例10:2-[4-(4-氯苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮(表-1中的化合物编号D009)的合成
将(4-氯苯甲酰基)哌啶盐酸盐(550mg,0.226mmol)、2-氯-3-甲基-6-(4-吡啶基)-嘧啶-4-酮(50mg,0.226mmol)和三乙胺(0.160ml,1.15mmol)的N,N-二甲基甲酰胺(1ml)溶液于60℃下搅拌。搅拌几小时之后,向该反应混合物中加入水。将沉淀物过滤出,用水洗涤并干燥,得到标题化合物(76mg,86%)。
以与上述方法相同的方式制备下表中的化合物。下表化合物中的化合物编号与上述表格的优选化合物中所示的相应。
表2
化合物编号 | 1H-NMR(Solvent)δ: | [M+H]+ |
A002 | (CDCl3):3.59(s,3H),5.00(dd,J=3.8,3.8Hz,2H),6.19(brs,1H),6.50(s,1H),7.24-7.37(m,2H),7.67(m,1H),7.78(d,J=5.1Hz,2H),8.04(m,1H),8.68(d,J=5.1Hz,2H). | 339 |
A003 | (CDCl3):3.60(s,3H),5.02(d,J=3.9Hz,2H),6.06(brs,1H),6.50(s,1H),7.26-7.88(m,6H),7.71(d,J=5.4Hz,2H). | 338 |
A004 | (CDCl3):3.41(s,3H),4.89(s,2H),6.48(s,1H),7.42(m,2H),7.70(dd,J=1.5Hz,4.5Hz,2H),7.92(br,1H),8.18(m,2H),8.49(dd,J=1.5Hz,4.5Hz,2H). | 339 |
A006 | (DMSO):3.39(s,3H),4.88(d,J=5.1Hz,2H),6.46(s,1H),7.58-8.08(m,6H),7.67(m,1H),8.48(d,J=5.1Hz,2H). | 355 |
A012 | (CDCl3):2.48(s,3H),3.60(s,3H),5.01(d,J=3.9Hz,2H),6.22(brs,1H),6.48(s,1H),7.43-7.49(m,2H),7.79(dd,J=4.5,1.8Hz,2H),7.86-7.89(m,2H),8.67(dd,J=4.5,1.8Hz,2H). | 335 |
B008 | (CDCl3):0.99(s,9H),2.89(m,1H),3.10-3.65(m,4H),3.53(s,3H),3.76(m,1H),4.04(m,1H),6.68(s,1H),7.80(d,J=6.0Hz,2H),8.72(d,J=6.0Hz,2H). | 328 |
B009 | (CDCl3):2.74(dd,J=13.7,7.4Hz,1H),2.87(dd,J=12.7,10.4Hz,1H),3.02(dd,J=13.7,6.2Hz,1H),3.24(td,J=12.2,3.0Hz,1H),3.39(s,3H),3.48(dd,J=15.1,1.6Hz,2H),3.77(td,J=11.7,2.4Hz,2H),3.91(m,1H),4.03(dd,J=11.6,2.0Hz,1H),6.65(s,1H),7.24-7.37(m,5H),7.71(dd,J=6.0,1.5Hz,2H),8.70(dd,J=6.0,1.5Hz,2H). | 363 |
B010 | (CDCl3):1.81(m,1H),1.93(m,1H),2.76(m,1H),2.89(m,1H),3.19(td,J=11.6,3.1Hz,1H),3.44(m,2H),3.49(s,3H),3.65(m,1H),3.81(td,J=11.5,2.0Hz,1H),4.06(dt,J=10.7,1.1Hz,1H),6.68(s,1H),7.21-7.34(m,5H),7.77(dd,J=4.6,1.5Hz,2H),8.73(dd,J=4.6,1.5Hz,2H). | 377 |
B011 | (CDCl3):1.49-1.90(m,4H),2.67(d,J=7.2Hz,2H),2.83(dd,J=12.8,10.5Hz,1H),3.15(td,J=11.9,2.8Hz,1H),3.45(d,J=12.8Hz,2H),3.52(s,3H),3.65(m,1H),3.79(dd,J=11.4,2.1Hz,1H),4.01(dd,J=11.1,1.5Hz,1H),6.68(s,1H),7.18-7.33(m,5H),7.79(dd,J=4.5,1.5Hz,2H),8.71(dd,J=4.8,1.5Hz,2H). | 391 |
B012 | (CDCl3):3.10-3.33(m,2H),3.50(m,1H),3.71-4.20(m,6H),6.70(s,1H),6.89-7.03(m,3H),7.24-7.36(m,2H),7.80(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 378 |
B027 | (DMSO-d6):3.01(m,1H),3.15(m,1H),3.47(s,3H),3.73(dd,J=13.5,13.5Hz,2H),3.90(dd,J=10.9,10.9Hz,1H),4.07(d,J=11.0Hz,1H),4.74(d,J=9.3Hz,1H),7.06(s,1H),7.30-7.47(m,5H),8.40(d,J=6.3Hz,2H),8.90(d,J=6.3Hz,2H). | 349 |
B028 | (DMSO-d6):3.01(m,1H),3.15(m,1H),3.47(s,3H),3.73(dd,J=13.4,13.4Hz,2H),3.90(dd,J=11.6,11.6Hz,1H),4.07(d,J=10.1Hz,1H),4.74(d,J=9.3Hz,1H),7.07(s,1H),7.30-7.46(m,5H),8.43(d,J=6.3Hz,2H),8.92(d,J=6.3Hz,2H). | 349 |
B029 | (DMSO-d6):3.02(m,1H),3.15(m,1H),3.47(s,3H),3.74(dd,J=13.4,13.4Hz,2H),3.90(dd,J=11.7,11.7Hz,1H),4.07(d,J=11.2Hz,1H),4.74(d,J=9.3Hz,1H),7.07(s,1H),7.30-7.47(m,5H),8.44(d,J=6.3Hz,2H),8.92(d,J=6.3Hz,2H). | 349 |
B030 | (DMSO-d6):3.00(dd,J=12.9,10.8,1H),3.18(m,1H),3.47(s,3H),3.73(dd,J=12.3,12.3Hz,2H),3.89(dd,J=9.9,9.9Hz,1H),4.07(d,J=11.2Hz,1H),4.75(d,J=9.3Hz,1H),7.04(s,1H),7.18-7.24(m,2H),7.47-7.52(m,2H),8.40(d,J=6.6Hz,2H),8.90(d,J=6.6Hz,2H). | 367 |
B031 | (DMSO-d6):3.01(dd,J=12.9,10.8,1H),3.18(m,1H),3.47(s,3H),3.74(dd,J=12.0,12.0Hz,2H),3.91(dd,J=11.7,11.7Hz,1H),4.08(d,J=10.5Hz,1H),4.75(d,J=9.3Hz,1H),7.05(s,1H),7.19-7.26(m,2H),7.48-7.54(m,2H),8.38(d,J=6.3Hz,2H),8.90(d,J=6.3Hz,2H). | 367 |
B032 | (DMSO-d6):3.01(dd,J=12.9,10.8,1H),3.19(m,1H),3.47(s,3H),3.73(dd,J=11,4,11,4Hz,2H),3.91(dd,J=11.4,11.4Hz,1H),4.08(d,J=11,4Hz,1H),4.75(d,J=9.3Hz,1H),7.04(s,1H),7.19-7.26(m,2H),7.48-7.54(m,2H),8.36(d,J=6.3Hz,2H),8.89(d,J=6.3Hz,2H). | 367 |
B033 | (DMSO-d6):3.00(m,1H),3.18(m,1H),3.47(s,3H),3.73-4.10(m,4H),4.77(d,J=9.4Hz,1H),7.05(s,1H),7.13-7.48(m,4H),8.38(d,J=6.0Hz,2H),8.89(d,J=6.0Hz,2H). | 367 |
B036 | (DMSO-d6):3.06(m,1H),3.22(m,1H),3.47(s,3H),3.68-4.11(m,4H),5.05(d,J=9.3Hz,1H),7.06(s,1H),7.22-7.61(m,4H),8.40(d,J=6.3Hz,2H),8.90(d,J=6.3Hz,2H). | 367 |
B037 | (DMSO-d6):3.04(m,1H),3.23(m,1H),3.46(s,3H),3.66-4.09(m,4H),5.04(d,J=9.6Hz,1H),7.05(s,1H),7.20-7.59(m,4H),8.39(d,J=6.0Hz,2H),8.88(d,J=6.0Hz,2H). | 367 |
B038 | (DMSO-d6):3.07(m,1H),3.24(m,1H),3.48(s,3H),3.69-4.10(m,4H),5.05(d,J=9.3Hz,1H),7.10(s,1H),7.21-7.61(m,4H),8.49(d,J=6.3Hz,2H),8.94(d,J=6.3Hz,2H). | 367 |
B039 | (DMSO-d6):2.97(dd,J=11.0,12.6Hz,1H),3.12-3.20(m,1H),3.45(s,3H),3.68-3.77(m,2H),3.85-3.92(m,1H),3.99-4.08(m,1H),4.73-4.76(m,1H),7.08(s,1H),7.42-7.49(m,4H),8.47(d,J=5.7Hz,2H),8.93(d,J=5.9Hz,2H). | 383 |
B042 | (DMSO-d6):3.02(dd,J=12.5,10.9,1H),3.19(m,1H),3.48(s,3H),3.71-4.11(m,4H),4.78(d,J=8.9Hz,1H),7.08(s,1H),7.38-7.53(m,4H),8.44(d,J=6.3Hz,2H),8.92(d,J=6.3Hz,2H). | 383 |
B045 | (DMSO-d6):2.93(dd,J=12.8,10.6,1H),3.23(m,1H),3.39(s,3H),3.69-4.15(m,4H),5,06(d,J=9.0Hz,1H),7.14(s,1H),7.38-7.66(m,4H),8.56(d,J=6.3Hz,2H),8.98(d,J=6.3Hz,2H). | 383 |
B046 | (DMSO-d6):2.89(m,1H),3.35(m,1H),3.50(s,3H),3.68-4.14(m,4H),5,06(m,1H),7.08(s,1H),7.39-7.64(m,4H),8.46(d,J=5.5Hz,2H),8.93(d,J=5.5Hz,2H). | 382 |
B048 | □(DMSO-d6):2.96(1H,dd,J=10.7,12.7Hz),3.12-3.20(1H,m),3.45(3H,s),3.66-3.75(2H,m),3.86-3.93(1H,m),4.05-4.09(1H,m),4.75(1H,d,J=8.9Hz),6.85(1H,s),7.42(2H,d,J=8.4Hz),7.58(2H,d,J=8.3Hz),7.97(2H,d,J=6.0Hz),8.69(2H,d,J=6.0Hz) | [M+]=427 |
B051 | (DMSO-d6):2.94-3.02(1H,m),3.14-3.22(1H,m),3.46(3H,s),3.66-3.77(2H,m),3.87-3.94(1H,m),4.04-4.09(1H,m),4.76(1H,d,J=9.5Hz),6.85(1H,s),7.33-7.38(1H,m),7.46-7.48(1H,m),7.52-7.55(1H,m),7.61-7.70(1H,m),7.97(2H,d,J=5.7Hz),8.68(2H,d,J=5.7Hz) | 427 |
B054 | (DMSO-d6):2.90(dd,J=12.6,10.5,1H),3.22(m,1H),3.51(s,3H),3.67-4.15(m,4H),4.98(d,J=9.0Hz,1H),7.07(s,1H),7.29-7.68(m,4H),8.42(d,J=6.3Hz,2H),8.90(d,J=6.3Hz,2H). | 427 |
B057 | (DMSO-d6):3.00(dd,J=12.6,10.5,1H),3.18(m,1H),3.47(s,3H),3.69-4.09(m,4H),4.70(d,J=9.3Hz,1H),7.06(s,1H),7.20(d,J=7.8Hz,2H),7.34(d,J=7.8Hz,2H),8.41(d,J=6.3Hz,2H),8.91(d,J=6.3Hz,2H). | 363 |
B060 | (DMSO-d6):2.33(s,3H),2.97-3.05(m,1H),3.15-3.22(m,1H),3.48(s,3H),3.70-3.77(m,1H),3.86-3.94(m,1H),4.05-4.09(m,1H),4.69-4.72(m,1H),7.07(s,1H),7.13-7.28(m,4H),8.43(d,J=6.0Hz,2H),8.92(d,J=6.3Hz,2H). | 363 |
B063 | (CDCl3):2.41(s,3H),3.08(m,1H),3.35(m,1H),3.54(m,1H),3.59(s,3H),3.66(m,1H),4.00(m,1H),4.21(m,1H),4.92(m,1H),6.69(s,1H),7.18-7.29(m,3H),7.55(m,1H),7.79(d,J=5.5Hz,2H),8.71(d,J=5.5Hz,2H). | 363 |
B064 | (CDCl3):2.41(s,3H),3.08(m,1H),3.35(m,1H),3.52-3.69(m,2H),3.60(s,3H),4.00(m,1H),4.21(m,1H),4.92(m,1H),6.69(s,1H),7.18-7.29(m,3H),7.53(m,1H),7.79(d,J=6.3Hz,2H),8.70(d,J=6.0Hz,2H). | 362 |
B066 | (DMSO-d6):3.11(dd,J=10.8,12.8Hz,1H),3.24-3.32(m,1H),3.47(s,3H),3.68-3.75(m,2H),3.90-3.98(m,1H),4.10-4.14(m,1H),4.96-4.99(m,1H),7.11(s,1H),7.60(t,J=7.4Hz,1H),7.77-7.79(m,2H),7.90(d,J=8.0Hz,1H),8.48(d,J=6.0Hz,2H),8.94(d,J=6.1Hz,2H). | 417 |
B069 | (DMSO-d6):3.04(m,1H),3.19(m,1H),3.48(s,3H),3.50-4.15(m,4H),4.87(d,J=8.7Hz,1H),7.04(s,1H),7.67(d,J=8.1Hz,2H),7.88(d,J=8.1Hz,2H),8.35(d,J=6.6Hz,2H),8.88(d,J=6.6Hz,2H). | 374 |
B072 | (DMSO-d6):3.02(m,1H),3.20(m,1H),3.49(s,3H),3.74(d,J=13.2Hz,2H),3.82(d,J=12.3Hz,2H),3.94(m,1H),4.11(d,J=11.1Hz,1H),4.83(d,J=9.9Hz,2H),7.08(s,1H),7.62(t,J=7.8Hz,1H),7.82(d,J=7.8Hz,2H),7.92(s,1H),8.43(d,J=5.7Hz,2H),8.92(d,J=5.7Hz,2H). | 374 |
B073 | (DMSO-d6):3.06(m,1H),3.12-3.85(m,6H),3.94(m,1H),4.11(d,J=9.9Hz,1H),4.83(d,J=9.0Hz,1H),7.00(s,1H),7.62(m,1H),7.83(d,J=7.8Hz,2H),7.92(s,1H),8.27(d,J=5.4Hz,2H),8.84(d,J=5.4Hz,2H). | 373 |
B075 | (DMSO-d6):3.09(m,1H),3.19-3.33(m,1H),3.49(s,3H),3.69(d,J=12.6Hz,1H),3.83(d,J=12.6Hz,1H),3.97(m,1H),4.12(d,J=11.7Hz,1H),5.02(dd,J=2.4Hz,10.5Hz,1H),6.86(s,1H),7.58(m,1H),7.73-7.82(m,2H),7.90(d,J=7.5Hz,1H),7.99(dd,J=1.5Hz,6.0Hz,2H),8.67(dd,J=1.5Hz,6.0Hz,2H). | 373 |
B078 | (DMSO-d6):3.01(m,1H),3.18(m,1H),3.47(s,3H),3.68-3.73(m,2H),3.75(s,3H),3.88(m,1H),4.06(m,1H),4.68(d,J=9.6Hz,1H),6.94(d,J=8.4Hz,2H),7.09(s,1H),7.37(d,J=8.4Hz,2H),8.46(d,J=6.0Hz,2H),8.94(d,J=6.0Hz,2H). | 379 |
B080 | (DMSO-d6):2.95-3.03(m,1H),3.12-3.20(m,1H),3.45(s,3H),3.67-3.71(m,2H),3.73(s,3H),3.82-3.90(m,1H),4.02-4.05(m,1H),4.64-4.67(m,1H),6.92(d,J=8.5Hz,2H),7.08(s,1H),7.35(d,J=8.5Hz,2H),8.49(d,J=6.2Hz,2H),8.96(d,J=6.0Hz,2H). | 379 |
B081 | (DMSO-d6):3.02(m,1H),3.15(m,1H),3.48(s,3H),3.70-3.75(m,2H),3.77(s,3H),3.90(m,1H),4.08(m,1H),4.73(d,J=9.6Hz,1H),6.89-7,04(m,3H),7.10(s,1H),7.31(m,1H),8.47(d,J=5,7Hz,2H),8.94(d,J=5.7Hz,2H). | 379 |
B082 | (DMSO-d6):2.99-3.06(m,1H),3.16-3.23(m,1H),3.48(s,3H),3.70-3.74(m,2H),3.77(s,3H),3.86-3.94(m,1H),4.07-4.10(m,1H),4.71-4.74(m,1H),6.89-6.92(m,1H),7.01(s,1H),7.06(m,2H),7.31(t,J=7.8Hz,1H),8.45(d,J=5.9Hz,2H),8.93(d,J=5.9Hz,2H). | 378 |
B084 | (DMSO-d6):2.82(dd,J=10.2,12.8Hz,1H),3.17-3.26(m,1H),3.50(s,3H),3.68-3.72(m,1H),3.83(s,3H),3.83-3.94(m,2H),4.09-4.13(m,1H),5.00-5.03(m,1H),6.98-7.07(m,2H),7.14(s,1H),7.29-7.35(m,1H),7.45(d,J=7.4Hz,1H),8.59(d,J=6.4Hz,2H),9.00(d,J=6.4Hz,2H). | 379 |
B085 | (CDCl3):2.83(1H,dd,J=10.2,12.9Hz),3..3-3.4(1H,m),3.5-3.6(1H,m),3.62(3H,s),3.8-3.9(1H,m),3.86(3H,m),4.0-4.1(1H,m),4.2-4.3(1H,m),5.08(1H,dd,J=2.1,10.2Hz),6.69(1H,s),7.0-7.1(1H,m),7.2-7.3(1H,m),7.53(1H,dd,J=1.5,7.8Hz),7.82(1H,dd,J=1.5,4.5Hz),8.71(2H,dd,1.5,4.5Hz) | 379 |
B087 | (DMSO-d6):1.30(3H,t,J=6.8Hz),2.75(1H,dd,J=10.6,12.5Hz),3.17-3.25(1H,m),3.48(3H,s),3.66-3.71(1H,m),3.77-3.81(1H,m),3.89-3.96(1H,m),4.01-4.13(3H,m),4.96(1H,d,J=9.3Hz),6.84(1H,s),6.95-7.03(2H,m),7.25-7.31(1H,m),7.42-7.44(1H,m),7.98(2H,d,J=5.1Hz),8.68(2H,d,J=5.3Hz) | 393 |
B088 | (CDCl3):2.90(m,1H),3.35(m,1H),3.55(m,1H),3.62(s,3H),3.69(m,1H),4.03(m,1H),4.24(m,1H),5.05(m,1H),6.71(s,1H),7.26-7.40(m,3H),7.68(m,1H),7.80(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 433 |
B089 | (CDCl3):2.80(m,1H),3.37(m,1H),3.53-3.73(m,2H),3.60(s,3H),4.05(m,1H),4.21-4.58(m,3H),5.08(m,1H),6.70(s,1H),6.86(d,1H,J=8.2Hz),7.14(m,1H),7.32(m,1H),7.59(m,1H),7.80(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 447 |
B090 | (DMSO-d6):2.82(dd,J=10.2,12.8Hz,1H),3.19-3.26(m,1H),3.49(s,3H),3.67-3.71(m,1H),3.83(s,3H),3.81-3.94(m,2H),4.09-4.12(m,1H),4.98-5.01(m,1H),7.05-7.23(m,4H),8.51(d,J=5.4Hz,2H),8.96(d,J=6.4Hz,2H). | 397 |
B091 | (DMSO-d6):2.81(m,1H),3.20(m,1H),3.47(s,3H),3.56-3.91(m,2H),3.83(s,3H),4.08(m,1H),4.95(d,J=9.3Hz,1H),6.78-6.98(m,2H),7.09(s,1H),7.43(m,1H),8.49(d,J=5.4Hz,2H),8.94(d,J=5.4Hz,2H). | 397 |
B092 | (DMSO-d6):2.94-3.01(1H,m),3.13-3.20(1H,m),3.46(3H,s),3.67-3.78(2H,m),3.88-3.95(1H,m),4.07-4.10(1H,m),4.79(1H,d,J=9.8Hz),6.86(1H,s),7.47(1H,d,J=8.3Hz),7.65-7.72(2H,m),7.98(2H,d,J=5.7Hz),8.68(2H,d,J=5.5Hz) | 417 |
B093 | (DMSO-d6):2.78(1H,dd,J=10.3,12.7Hz),3.16-3.24(1H,m),3.46(3H,s),3.62-3.66(1H,m),3.71(3H,s),3.78(3H,s),3.83-4.11(2H,m),4.97(1H,d,J=9.0Hz),6.84(1H,s),6.85-6.88(1H,m),6.95-7.00(2H,m),7.99(2H,d,J=5.6Hz),8.69(2H,d,J=5.9Hz) | 409 |
B094 | (DMSO-d6):2.78-2.86(m,1H),3.17-3.25(m,1H),3.49(s,3H),3.66-3.93(m,3H),3.72(s,3H),3.78(s,3H),4.09-4.13(m,1H),4.96-4.99(m,1H),6.85-7.09(m,4H),8.48(d,J=5.4Hz,2H),8.94(d,J=6.0Hz,2H). | 408 |
B096 | (CDCl3):3.07(t,J=10.6Hz,1H),3.29(td,J=10.3,3.2Hz,1H),3.53(d,J=12.2Hz,1H),3.58(s,3H),3.68(dt,J=13.1,1.1Hz,1H),3.96(td,J=11.9,2.3Hz,1H),4.19(dd,J=13.9,2.3Hz,1H),4.75(dd,J=10.4,1.1Hz,2H),6.72(s,1H),6.80(tt,J=8.9,2.3Hz,1H),6.96(dd,J=6.0,2.3Hz,2H),7.79(dd,J=4.6,1.6Hz,2H),8.73(dd,J=4.5,1.6Hz,2H). | 385 |
B097 | (CDCl3):2.78(dd,J=12.8,10.4Hz,1H),3.32(td,J=12.2,3.2Hz,1H),3.54(d,J=12.5Hz,1H),3.62(s,3H),3.82(dt,J=12.9,1.9Hz,1H),4.02(td,J=11.8,2.3Hz,1H),4.23(dd,J=11.6,2.2Hz,1H),5.02(dd,J=10.3,1.9Hz,2H),6.71(s,1H),7.24(dd,J=6.9,2.8Hz,1H),7.50(dd,J=11.2,8.4Hz,1H),7.80(dd,J=4.6,1.5Hz,2H),8.70(dd,J=4.5,1.5Hz,2H). | 419 |
B098 | (CDCl3):2.78(dd,J=12.8,10.4Hz,1H),3.32(td,J=12.2,3.2Hz,1H),3.54(d,J=12.5Hz,1H),3.62(s,3H),3.82(dt,J=12.9,1.9Hz,1H),4.02(td,J=11.8,2.3Hz,1H),4.23(dd,J=11.6,2.2Hz,1H),5.02(dd,J=10.3,1.9Hz,2H),6.71(s,1H),7.24(dd,J=6.9,2.8Hz,1H),7.50(dd,J=11.2,8.4Hz,1H),7.80(dd,J=4.6,1.5Hz,2H),8.70(dd,J=4.5,1.5Hz,2H). | 418 |
B100 | (DMSO-d6):2.90(dd,J=10.5Hz,12.9Hz,1H),3.23(m,1H),3.51(s,3H),3.70(d,J=13.2Hz,1H),3.85(d,J=12.9Hz,1H),3.95(m,1H),4,12(d,J=9.6Hz,1H),4.96(d,J=8.7Hz,1H),7.11(s,1H),7.37(m,1H),7.60-7.70(m,2H),8.50(d,J=6.3Hz,2H),8.95(d,J=6.6Hz,2H). | 446 |
B101 | (DMSO-d6):3.07(dd,J=12.8,10.6,1H),3.24(m,1H),3.47(s,3H),3.67-4.09(m,4H),5.01(d,J=9.4Hz,1H),7.06(s,1H),7.17(m,1H),7.32(m,1H),7.61(m,1H),8.41(d,J=6.3Hz,2H),8.90(d,J=6.3Hz,2H). | 384 |
B102 | (DMSO-d6):3.22(t,J=14.4Hz,1H),3.58(d,J=19.5Hz,1H),3.77(s,3H),3.26-4.04(m,4H),5.29(d,J=9.0Hz,1H),6.67(d,J=8.4Hz,2H),7.02(s,1H),7.27(t,J=8.4Hz,1H),8.44(d,J=5.7Hz,2H),8.92(d,J=5.7Hz,2H). | 408 |
B103 | d(DMSO-d6):3.22(1H,t,J=14.4Hz),3.58(1H,d,J=19.5Hz),3.77(3H,s),3.26-4.04(4H,m),5.29(1H,d,J=9.0Hz),6.67(2H,d,J=8.4Hz),7.02(1H,s),7.27(1H,t,J=8.4Hz),8.44(2H,d,J=5.7Hz),8.92(2H,d,J=5.7Hz). | 409 |
B104 | d(DMSO-d6):3.22(1H,t,J=14.4Hz),3.58(1H,d,J=19.5Hz),3.77(3H,s),3.26-4.04(4H,m),5.29(1H,d,J=9.0Hz),6.67(2H,d,J=8.4Hz),7.02(1H,s),7.27(1H,t,J=8.4Hz),8.44(2H,d,J=5.7Hz),8.92(2H,d,J=5.7Hz). | 409 |
B105 | (DMSO-d6):3.44-3.63(m,2H),3.58(s,3H),3.81(m,1H),3.98(m,1H),4.21(m,1H),5.55(dd,J=2.7Hz,11.1Hz,1H),6.69(s,1H),7.20(t,J=7.5Hz,1H),7.35(d,J=7.5Hz,2H),7.82(d,J=4.5Hz,2H),8.70(d,J=4.5Hz,2H). | 416 |
B106 | (CDCl3):3.44-3.55(3H,m),3.59(3H,s),3.82(1H,dd,J=12.9,10.8Hz),3.98(1H,m),4.20(1H,m),5.55(1H,dd,J=10.8,2.7Hz),6.70(1H,s),7.18-7.38(3H,m),7.82(2H,dd,J=4.5,1.5Hz),8.71(2H,dd,J=4.5,1.8Hz). | 417 |
B107 | (CDCl3):3.44-3.55(3H,m),3.59(3H,s),3.82(1H,dd,J=12.9,10.8Hz),3.98(1H,m),4.20(1H,m),5.55(1H,dd,J=10.8,2.7Hz),6.70(1H,s),7.18-7.38(3H,m),7.82(2H,dd,J=4.5,1.5Hz),8.71(2H,dd,J=4.5,1.8Hz). | 417 |
B108 | (DMSO-d6):3.03(t,J=12.6Hz,1H),3.20(t,J=11.1Hz,1H),3.48(s,3H),3.70-3.78(m,2H),3.90(m,1H),4.05(m,1H),4.73(d,J=10.2Hz),7.03(m,1H),7.06(s,1H),7.18-7.25(m,2H),8.40(d,J=5.7Hz,2H),8.90(d,J=5.7Hz,2H). | 396 |
B109 | (CDCl3):3.42-3.52(2H,m),3.57(3H,s),3.63-3.66(2H,m),3.67(1H,m),4.13(1H,m),5.24(1H,dd,J=9.0,1.8Hz),6.70(1H,s),6.95(2H,m),7.32(1H,m),7.82(2H,dd,J=4.5,1.8Hz),8.72(2H,dd,J=4.5,1.8Hz). | 410 |
B110 | (CDCl3):3.42-3.52(2H,m),3.57(3H,s),3.63-3.66(2H,m),3.67(1H,m),4.13(1H,m),5.24(1H,dd,J=9.0,1.8Hz),6.70(1H,s),6.95(2H,m),7.32(1H,m),7.82(2H,dd,J=4.5,1.8Hz),8.72(2H,dd,J=4.5,1.8Hz). | 385 |
B112 | (CDCl3):1.74-1.79(m,4H),2.50-2.53(m,4H),3.13(m,1H),3.32(m,1H),3.51-3.68(m,2H),3.64(s,3H),3.67(s,2H),4.00(m,1H),4.18(m,1H),4.72(m,1H),6.70(s,1H),7.33-7.44(m,4H),7.80(dd,J=4.8,1.2Hz,2H),8.71(dd,J=4.8,1.2Hz,2H). | 432 |
B113 | (CDCl3):1.80-1.82(4H,m),2.56-5.58(4H,m),3.12(1H,dd,J=13.2,10.8Hz),3.32(1H,m),3.54(1H,m),3.58(3H,s),3.64(1H,m),3.68(2H,s),3.98-4.21(2H,m),4.73(1H,dd,J=10.5,2.1Hz),6.69(1H,s),7.35-7.42(4H,m),7.79(2H,d,J=4.5,1.5Hz),8.71(2H,d,J=4.5,1.5Hz). | 431 |
B115 | (D2O):1.24-1.39(1H,m),1.46-1.67(3H,m),1.75-1.80(2H,m),2.78-2.86(2H,m),3.14-3.34(4H,m),3.44(3H,s),3.66-3.72(2H,m),3.91-4.06(2H,m),4.16(2H,s),4.79(1H,d,J=10.4Hz),6.83(1H,s),7.35-7.47(4H,m),8.44(2H,d,J=6.5Hz),8.72(2H,d,J=6.6Hz) | 446 |
B116 | (D2O):1.81-1.96(2H,m),2.00-2.16(2H,m),3.03-3.15(2H,m),3.19-3.31(2H,m),3.39-3.47(2H,m),3.50(3H,s),3.70-3.78(2H,m),3.95-4.11(2H,m),4.31(2H,s),4.85(2H,d,J=10.3Hz),6.89(1H,s),7.41-7.56(4H,m),8.49(2H,d,J=6.0Hz),8.77(2H,d,J=6.7Hz) | 432 |
B117 | (D2O):2.74(6H,s),3.17-3.34(2H,m),3.48(3H,s),3.68-3.76(2H,m),3.97-4.09(2H,m),4.23(2H,s),4.83(1H,d,J=9.9Hz),6.87(1H,s),7.39-7.52(4H,m),8.46(2H,d,J=7.1Hz),8.75(2H,d,J=6.6Hz) | 406 |
B118 | (D2O):3.11-3.25(4H,m),3.31-3.36(2H,m),3.48(3H,s),3.62-3.76(4H,m),3.98-4.06(4H,m),4.30(2H,s),4.83(1H,d,J=8.9Hz),6.87(1H,s),7.41-7.52(4H,m),8.47(2H,d,J=6.8Hz),8.76(2H,d,J=6.6Hz) | 448 |
B119 | (CDCl3):1.61-1.78(4H,m),2.34-2.48(4H,m),3.06(1H,dd,J=10.5,12.9Hz),3.24-3.28(1H,m),3.35-3.45(1H,m),3.54(3H,s),3.68-3.81(2H,m),3.98-4.02(1H,m),4.03-4.20(2H,m),5.05(1H,dd,J=2.1,10.2Hz),6.68(1H,s),7.25-7.26(2H,m),7.32-7.36(1H,m),7.57-7.60(1H,m),7.81(2H,d,J=6.3Hz),8.72(2H,d,J=6.0Hz) | 431 |
B120 | (CDCl3):1.31(3H,d,J=6.0Hz),1.37(3H,d,J=6.1Hz),2.76(1H,dd,J=10.1,12.6Hz),3..3-3.5(1H,m),3.5-3.7(1H,m),3.63(3H,s),3.7-3.8(1H,m),4.0-4.2(1H,m),4.2-4.3(1H,m),4.6-4.7(1H,m),5.02(1H,dd,J=2.0,10.1Hz),6.68(1H,s),6.88(1H,d,J=8.3Hz),6.98(1H,t,J=7.4Hz),7.2-7.3(1H,m),7.52(1H,dd,J=1.6,7.6Hz),7.81(1H,dd,J=1.6,4.5Hz),8.71(2H,dd,1.5,4.5Hz) | 407 |
B122 | (CDCl3):1.34(6H,d,J=6.0Hz),3.13(1H,dd,J=10.8,12.9Hz),3.2-3.4(1H,m),3.5-3.7(2H,m),3.57(3H,s),3.9-4.0(1H,m),4.1-4.2(1H,m),4.5-4.6(1H,m),4.66(1H,dd,J=2.1,10.5Hz),6.69(1H,s),6.9-7.0(2H,m),7.3-7.4(2H,m),7.79(2H,dd,J=1.8,4.5Hz),8.71(2H,dd,J=1.8,4.5Hz). | 407 |
B126 | (CDCl3):0.3-0.4(2H,m),0.6-0.7(2H,m),1.2-1.3(1H,m),2.79(1H,dd,J=10.2,12.9Hz),3..3-3.5(1H,m),3.6-3.7(1H,m),3.65(3H,s),3.7-4.0(3H,m),4.0-4.1(1H,m),4.2-4.3(1H,m),5.09(1H,dd,J=2.1,10.2Hz),6.68(1H,s),6.84(2H,d,J=8.1Hz),7.03(2H,t,J=7.5Hz),7.2-7.3(1H,m),7.53(1H,dd,J=1.5,7.5Hz),7.81(1H,dd,J=1.5,4.5Hz),8.71(2H,dd,1.5,4.5Hz) | 419 |
B128 | (CDCl3):0.3-0.4(2H,m),0.6-0.7(2H,m),1.2-1.3(1H,m),3.12(1H,dd,J=10.8,12.9Hz),3.2-3.4(1H,m),3.5-3.7(2H,m),3.57(3H,s),3.82(2H,d,J=6.9Hz),3.9-4.0(1H,m),4.1-4.2(1H,m),4.67(1H,dd,J=2.4,10.8Hz),6.69(1H,s),6.93(2H,d,J=8.7Hz),7.32(2H,d,J=8.7Hz),7.79(2H,dd,J=1.8,4.8Hz),8.71(2H,dd,J=1.8,4.8Hz). | 419 |
B130 | (DMSO-d6):2.98(1H,dd,J=12.6,14.4Hz),3.18-3.24(1H,m),3.22(3H,s),3.46(3H,s),3.69(1H,d,J=12.3Hz),3.81(1H,d,J=12.9Hz),3.89-3.96(1H,m),4.10(1H,d,J=10.5Hz),4.89(1H,d,J=9.0Hz),6.83(1H,s),7.67(1H,t,J=7.8Hz),7.80(1H,d,J=7.5Hz),7.88(1H,d,J=6.9Hz),7.96(2H,d,J=5.1Hz),8.00(1H,s),8.67(2H,d,J=5.1Hz) | 427 |
B140 | (CDCl3):2.0-2.1(4H,m),3.16(1H,dd,J=10.7,12.8Hz),3.2-3.4(5H,m),3.5-3.7(2H,m),3.56(3H,s),3.9-4.0(1H,m),4.1-4.2(1H,m),4.61(1H,dd,J=2.1,10.7Hz),6.57(2H,d,J=8.4Hz),6.69(1H,s),7.26(2H,d,J=8.7Hz),7.80(2H,dd,J=1.4,4.6Hz),8.71(2H,dd,J=1.4,4.6Hz) | 418 |
B143 | (CDCl3):3.18(1H,dd,J=12.3,10.1Hz),3.35(1H,m),3.59(1H,m),3.60(3H,s),3.72(1H,m),3.98-4.23(2H,m),4.79(1H,d,J=10.5),6.70(1H,s),7.35-7.65(9H,m),7.80(2H,d,J=5.7Hz),8.72(2H,d,J=5.7Hz). | 425 |
B184 | (DMSO-d6):1.99-2.06(2H,m),2.82-2.89(4H,m),2.98(1H,dd,J=10.7,12.9Hz),3.11-3.22(1H,m),3.45(3H,s),3.65-3.70(2H,m),3.84-3.92(1H,m),4.01-4.06(1H,m),4.79(1H,d,J=8.7Hz),6.83(1H,s),7.17-7.23(2H,m),7.29-7.32(1H,m),7.96(2H,d,J=6.2Hz),8.66(2H,d,J=6.0Hz) | 389 |
B185 | (DMSO-d6):3.07(1H,dd,J=10.9,12.3Hz),3.18-3.27(1H,m),3.49(3H,s),3.70-3.74(1H,m),3.81-3.86(1H,m),3.93-4.00(1H,m),4.11-4.15(1H,m),4.93(1H,d,J=9.5Hz),6.86(1H,s),7.51-7.56(2H,m),7.59-7.62(1H,m),7.91-7.99(6H,m),8.68(2H,d,J=5.0Hz) | 399 |
B186 | (CDCl3):3.21(1H,dd,J=10.5,13.2Hz),3.31-3.41(1H,m),3.54-3.67(1H,m),3.61(3H,s),3.74-3.78(1H,m),4.01-4.10(1H,m),4.23-4.28(1H,m),4.92(1H,dd,J=2.1,10.5Hz),6.71(1H,s),7.50-7.54(3H,m),7.80(2H,d,J=6.0Hz),7.82-7.91(4H,m),8.71(2H,d,J=6.0Hz) | 398 |
B187 | (DMSO-d6):3.18(dd,J=10.5,12.9Hz,1H),3.31-3.38(m,1H),3.53(s,3H),3.75-3.79(m,1H),4.00-4.18(m,3H),5.52-5.55(m,1H),7.03(s,1H),7.51-8.30(m,7H),8.42(d,J=6.0Hz,2H),8.92(d,J=5.4Hz,2H). | 399 |
B188 | (CDCl3):3.09-3.33(4H,m),3.53-3.64(2H,m),3.57(3H,s),3.95-4.02(1H,m),4.13-4.20(1H,m),4.58(2H,d,J=8.7Hz),4.65(1H,dd,J=2.1,10.8Hz),6.70(1H,s),6.78-6.81(1H,m),7.13-7.16(1H,m),7.25-7.30(1H,m),7.80(2H,d,J=6.0Hz),8.71(2H,d,J=6.0Hz) | 390 |
B189 | (DMSO-d6):3.07-3.27(m,2H),3.48(s,3H),3.77(d,J=13.2Hz,1H),3.93-4.02(m,2H),4.13(d,J=10.2Hz,1H),5.03(d,J=8.7Hz,1H),7.13(s,1H),8.05(m,1H),8.55(d,J=6.3Hz,2H),8.61(d,J=8.1Hz,1H),8.90(d,J=5.4Hz,2H),8.97(d,J=5.4Hz,2H). | 388 |
B190 | (DMSO-d6):3.09-3.23(m,2H),3.47(s,3H),3.68(d,J=12.6Hz,1H),3.87-3.94(m,2H),4.03(d,J=11.8Hz,1H),5.05(D,J-8.4Hz,1H),7.05(m,1H),7.08(s,1H),7.17(d,J=3.3Hz,1H),7.53(d,J=5.1Hz,1H),8.44(d,J=6.4Hz,2H),8.93(d,J=6.4Hz,2H). | 354 |
B191 | (DMSO-d6):3.03-3.22(m,2H),3.45(s,3H),3.69-4.04(m,4H),4.80(d,J=10.4Hz,1H),7.03(s,1H),7.19(m,1H),7.52-7.55(m,2H),8.39(d,J=5.4Hz,2H),8.90(d,J=5.4Hz,2H). | 354 |
B194 | (DMSO-d6):3.18(m,1H),3.50(s,3H),3.73-4.17(m,5H),5.03(d,J=8.4Hz,1H),7.15(s,1H),7.65(m,1H),7.82(d,J=7.8Hz,1H),8.20(t,J=7.8Hz,1H),8.57(d,J=6.6Hz,2H),8.72(d,J=4.5Hz,1H),8.98(d,J=6.6Hz,2H). | 349 |
B195 | (DMSO-d6):3.07-3.27(m,2H),3.48(s,3H),3.77(d,J=13.2Hz,1H),3.93-4.02(m,2H),4.13(d,J=10.2Hz,1H),5.03(d,J=8.7Hz,1H),7.13(s,1H),8.05(m,1H),8.55(d,J=6.3Hz,2H),8.61(d,J=8.1Hz,1H),8.90(d,J=5.4Hz,1H),8.90(d,J=5.4Hz,1H),8.97(d,J=6.3Hz,2H). | 349 |
B200 | (DMSO-d6):3.30(s,3H),3.36(m,2H),3.88(m,2H),4.01(m,2H),7.10(s,1H),7.22-7.42(m,10H),8.46(d,J=6.4Hz,2H),8.93(d,J=6.3Hz,2H). | 425 |
B202 | (DMSO-d6):1.60-2.00(m,3H),2.62-2.76(m,3H),3.18-3.29(m,2H),3.48(s,3H),3.68-3.83(m,3H),4.10-4.17(m,1H),7.03(s,1H),7.10-7.24(m,3H),7.63-7.66(m,1H),8.38(d,J=6.1Hz,2H),8.89(d,J=6.0Hz,2H). | 388 |
B203 | (CDCl3):2.20-2.40(m,1H),2.60-2.70(m,1H),2.80-3.00(m,1H),3.00-3.20(m,1H),3.29-3.50(m,4H),3.59(s,3H),4.03-3.20(m,2H),6.70(s,1H),7.27-7.36(m,3H),7.49-7.51(m,1H),7.78(dd,J=1.5,4.8Hz,2H),8.70(dd,J=1.8,4.5Hz,2H). | 374 |
B205 | (DMSO-d6):1.30(s,3H),1.44(s,3H),2.80-2.95(m,2H),3.51(s,3H),3.63-3.80(m,2H),5.07(m,1H),7.03(s,1H),7.30-7.48(m,5H),8.35(br s,2H),8.89(br s,2H). | 377 |
B217 | (CDCl3):1.39(s,3H),1.52(s,3H),2.89-3.03(m,2H),3.39(m,1H),3.59(s,3H),3.63(m,1H),3.82(s,3H),5.00(m,1H),6.69(s,1H),6.93(d,J=8.7Hz,2H),7.37(d,J=8.7Hz,2H),7.79(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 407 |
B219 | 2.97(1H,dd,J=10.5,12.9Hz),3.30-3.39(1H,m),3.53-3.66(1H,m),3.60(3H,s),3.75-3.89(1H,m),3.82(3H,s),3.95-4.03(1H,m),4.18-4.23(1H,m),5.07(1H,d,J=9.6Hz),6.71(1H,s),6.79-6.85(1H,m),6.97-7.04(1H,m),7.07-7.10(1H,m),7.82(2H,d,J=6.0Hz),8.72(2H,d,J=6.0Hz)(CDCl3) | 396 |
B220 | 2.79(1H,dd,J=10.1,12.7Hz),3.29-3.38(1H,m),3.54-3.59(1H,m),3.61(3H,s),3.79-3.83(1H,m),3.84(3H,s),3.94-3.99(1H,m),4.19-4.23(1H,m),5.02(1H,dd,J=2.1,10.1Hz),6.69(1H,s),6.77(1H,d,J=8.8Hz),7.40(1H,dd,J=2.6,8.7Hz),7.66(1H,d,J=2.3Hz),7.82(2H,d,J=6.1Hz),8.71(2H,d,J=6.1Hz)(CDCl3) | 457 |
B221 | (DMSO-d6):1.40-1.60(m,1H),1.80-2.20(m,2H),2.60-3.00(m,5H),3.00-3.20(m,1H),3.45(s,3H),3.50-3.70(m,2H),3.73(d,J=11.4Hz,1H),3.81(d,J=12.6Hz,1H),3.98(d,J=12.3Hz,1H),7.01(s,1H),7.02-7.10(m,4H),8.38(dm,J=6.6Hz,2H),8.88-8.92(m,2H). | 402 |
B225 | (CDCl3):3.3-3.5(2H,m),3.63(3H,s),3.5-3.7(1H,m),4.0-4.2(2H,m),4.2-4.3(1H,m),5.20(1H,dd,J=2.7,9.8Hz),6.73(1H,s),7.4-7.6(2H,m),7.80(1H,d,J=6.3Hz),7.94(1H,d,J=7.9Hz),8.03(1H,d,J=8.0Hz),8.71(1H,d,J=6.3Hz) | 406 |
B234 | (DMSO-d6);3.01(m,1H),3.17(m,1H),3.46(s,3H),3.70(m,2H),3.89(m,1H),4.05(d,J=12.0Hz,1H),4.65(d,J=8.7Hz,1H),6.02(s,2H),6.89-6.96(m,2H),7.01(s,2H),8.34(d,J=6.6Hz,2H),8.87(d,J=6.6Hz,2H). | 393 |
B235 | (DMSO-d6);2.99(dd,J=10.8Hz,12.9Hz,1H),3.12(m,1H),3.46(s,3H),3.69(d,J=12.9,2H),3.87(m,1H),4.04(d,J=11.7Hz,1H),4.24(s,4H),4.62(d,J=9.0Hz,1H),6.83-6.94(m,3H),7.05(s,1H),8.41(d,J=6.6Hz,2H),8.91(d,J=6.6Hz,2H). | 407 |
B236 | (DMSO-d6);3.04(m,1H),3.19(m,1H),3.47(s,3H),3.69-4.09(m,6H),3.75(s,3H),3.77(s,3H),4.67(d,J=9.0Hz,1H),6.93-7.05(m,4H),8.38(d,J=6.3Hz,2H),8.89(d,J=6.3Hz,2H). | 409 |
B237 | (DMSO-d6):2.5-2.6(1H,m),2.9-3.2(6H,m),3.44(3H,s),3.4-3.8(4H,s),3.9-4.0(1H,m),6.99(1H,s),7.1-7.2(2H,m),7.2-7.3(2H,m),7.88(1H,d,J=6.9Hz),8.31(2H,d,J=6.3Hz),8.00(1H,s),8.88(2H,d,J=6.5Hz) | 389 |
B238 | (DMSO):3.05(1H,dd,J=10.8,12.8Hz),3.15-3.26(1H,m),3.45(3H,s),3.65(1H,d,J=13.4Hz),3.73-3.91(2H,m),3.79(3H,s),4.05(1H,d,J=13.6Hz),4.95(1H,d,J=8.9Hz),6.82-6.89(3H,m),7.43-7.49(1H,m),7.98(2H,d,J=5.9Hz),8.68(2H,d,J=5.8Hz) | 397 |
B239 | (DMSO):2.88(1H,dd,J=10.2,13.0Hz),3.19-3.27(1H,m),3.47(3H,s),3.66(1H,d,J=13.4Hz),3.85(1H,d,J=13.4Hz),3.93(1H,t,J=11.6Hz),4.11(1H,d,J=9.6Hz),5.03(1H,d,J=8.5Hz),6.84(1H,s),7.50-7.54(1H,m),7.63-7.67(2H,m),7.97(2H,d,J=6.0Hz),8.67(2H,d,J=5.9Hz) | 417 |
B240 | (CDCl3):3.00(1H,dd,J=12.9,10.5Hz),3.21-3.41(3H,m),3.55(1H,m),3.59(3H,s),3.83-4.21(3H,m),4.61(2H,m),4.95(1H,d,J=8.4Hz),6.69(1H,s),6.91(1H,m),7.16-7.31(2H,m),7.84(2H,dd,J=4.5,1.5Hz),8.71(2H,dd,J=4.5,1.5Hz). | 391 |
B241 | (DMSO-d6):2.80(1H,dd,J=10.2,12.9Hz),3.1-3.3(1H,m),3.46(3H,s),3.6-3.7(1H,m),3.77(3H,s),3.82(3H,s),3.7-3.9(2H,m),4.0-4.1(1H,m),4.9-5.0(1H,m),6.5-6.6(2H,m),6.82(1H,s),7.3-7.4(1H,m),7.79(2H,dd,J=1.5,4.5Hz),8.69(2H,dd,J=1.5,4.5Hz). | 409 |
B242 | (DMSO-d6):2.80(1H,dd,J=10.2,12.9Hz),3.1-3.3(1H,m),3.46(3H,s),3.6-3.7(1H,m),3.77(3H,s),3.82(3H,s),3.7-3.9(2H,m),4.0-4.1(1H,m),4.9-5.0(1H,m),6.5-6.6(2H,m),6.82(1H,s),7.3-7.4(1H,m),7.79(2H,dd,J=1.5,4.5Hz),8.69(2H,dd,J=1.5,4.5Hz). | 409 |
B243 | (DMSO-d6):2.7-2.9(1H,m),3.1-3.3(1H,m),3.46(3H,s),3.6-3.7(1H,m),3.89(3H,s),3.90(3H,s),3.7-3.9(2H,m),4.0-4.1(1H,m),4.9-5.0(1H,m),6.80(1H,s),6.83(1H,s),7.51(1H,s),7.9-8.0(2H,m),8.6-8.7(2H,m) | 488 |
B244 | (DMSO-d6):2.80(1H,dd,J=10.2,12.9Hz),3.1-3.3(1H,m),3.46(3H,s),3.6-3.7(1H,m),3.77(3H,s),3.82(3H,s),3.7-3.9(2H,m),4.0-4.1(1H,m),4.9-5.0(1H,m),6.5-6.6(2H,m),6.82(1H,s),7.3-7.4(1H,m),7.79(2H,dd,J=1.5,4.5Hz),8.69(2H,dd,J=1.5,4.5Hz). | 409 |
B245 | (CDCl3):2.80(1H,dd,J=12.6,10.4Hz),3.33(1H,m),3.55(1H,m),3.62(3H,s),3.77(1H,m),3.85(3H,s),4.01(1H,m),4.21(1H,m),5.02(1H,d,J=9.6Hz),6.61-6.75(3H,m),7.48(1H,m),7.82(2H,d,J=5.7Hz),8.71(2H,d,J=5.7Hz). | 397 |
B246 | (CDCl3):3.18(1H,dd,J=12.3,10.1Hz),3.35(1H,m),3.59(1H,m),3.60(3H,s),3.72(1H,m),3.98-4.23(2H,m),4.79(1H,d,J=10.5),6.71(1H,s),7.36-7.66(9H,m),7.80(2H,d,J=5.7Hz),8.72(2H,d,J=5.7Hz). | 425 |
B247 | (CDCl3):0.32-0.34(2H,m),0.62-0.67(2H,m),1.22(1H,m),2.76(1H,dd,J=12.6,10.2Hz),3.37(1H,m),3.60-4.25(7H,m),3.65(3H,s),5.02(1H,d,J=9.3Hz),6.54-6.72(3H,m),7.47(1H,dd,J=8.1,7.2Hz),7.81(2H,d,J=6.0Hz),8.71(2H,d,J=6.0Hz). | 437 |
B248 | (CDCl3):1.33(3H,d,J=6.0Hz),1.38(3H,d,J=6.0Hz),2.72(1H,dd,J=12.6,10.2Hz),3.35(1H,m),3.57-3.72(5H,m),4.03-4.25(2H,m),4.57(1H,m),4.95(1H,d,J=8.7Hz),6.58-6.71(3H,m),7.46(1H,dd,J=8.4,7.2Hz),7.80(2H,d,J=6.0Hz),8.71(2H,d,J=6.0Hz). | 425 |
B249 | (DMSO):2.98(1H,dd,J=10.5,13.0Hz),3.18-3.30(1H,m),3.47(3H,s),3.66(1H,d,J=12.5Hz),3.80(1H,d,J=13.0Hz),3.84(3H,s),3.92(1H,dd,J=9.5,11.7Hz),4.18(1H,d,J=11.7Hz),5.01(1H,dd,J=2.0,10.4Hz),6.84(1H,s),7.50(1H,d,J=2.6Hz),7.67(1H,d,J=2.7Hz),7.99(2H,d,J=6.2Hz),8.69(2H,d,J=6.1Hz) | 447 |
B250 | (DMSO):3.01(1H,dd,J=10.8,12.9Hz),3.14-3.18(1H,m),3.46(3H,s),3.66-3.76(2H,m),3.86-3.93(1H,m),4.06(1H,d,J=11.7Hz),4.74(1H,d,J=8.7Hz),6.84(1H,s),6.98-7.04(4H,m),7.11-7.18(1H,m),7.37-7.48(4H,m),7.97(2H,d,J=6.3Hz),8.69(2H,d,J=6.0Hz) | 441 |
B251 | (CDCl3):3.06(1H,dd,J=12.9,10.5Hz),3.42(1H,m),3.60(1H,m),3.67(3H,s),4.07-4.32(3H,m),5.38(1H,d,J=10.2Hz),6.73(1H,s),7.45-7.61(2H,m),7.82(1H,d,J=9.0Hz),7.89(2H,d,J=6.0Hz),8.72(2H,d,J=6.0Hz). | 391 |
B252 | (CDCl3):3.3-3.7(4H,m),3.58(3H,s),3.96(1H,t,J=11.7Hz),4.17(1H,dd,J=4.5,8.3Hz),6.70(1H,s),7.0-7.1(1H,m),7.2-7.4(2H,m),7.82(2H,d,J=5.7Hz),8.71(2H,d,J=5.6Hz) | 401 |
B253 | (CDCl3):2.81(1H,dd,J=10.5,12.8Hz),3.3-3.4(1H,m),3.5-3.7(2H,m),3.63(3H,s),3.7-3.9(1H,m),4.03(1H,dt,J=2.2,11.6Hz),4.2-4.3(1H,m),5.0-5.1(1H,m),6.71(1H,s),7.0-7.2(2H,m),7.63(1H,dd,J=6.3,8.7Hz),7.80(2H,d,J=6.0Hz),8.71(2H,d,J=5.6Hz). | 401 |
B254 | (DMSO):2.89(1H,dd,J=10.2,12.8Hz),3.19-3.30(1H,m),3.49(3H,s),3.67(1H,d,J=13.0Hz),3.86-3.95(2H,m),3.89(3H,s),4.13(1H,d,J=9.8Hz),5.07(1H,d,J=8.4Hz),6.84(1H,s),7.15(1H,d,J=8.6Hz),7.29-7.37(1H,m),7.42-7.48(2H,m),7.60-7.63(3H,m),7.72(1H,d,J=2.3Hz),8.00(2H,d,J=6.1Hz),8.69(2H,d,J=6.0Hz) | 455 |
B255 | (DMSO):2.85(1H,dd,J=10.2,12.9Hz),3.19-3.28(1H,m),3.49(3H,s),3.67(1H,d,J=12.3Hz),3.85-3.95(2H,m),3.88(3H,s),4.13(1H,d,J=9.7Hz),5.06(1H,d,J=8.3Hz),6.84(1H,s),7.14(1H,d,J=8.6Hz),7.21-7.30(2H,m),7.57-7.70(4H,m),8.00(2H,d,J=6.1Hz),8.69(2H,d,J=6.1Hz) | 473 |
B256 | (DMSO):2.93(1H,dd,J=10.3,13.0Hz),3.19-3.31(1H,m),3.49(3H,s),3.68(1H,d,J=12.6Hz),3.86-3.95(2H,m),3.90(3H,s9),4.13(1H,d,J=9.5Hz),5.08(1H,d,J=8.3Hz),6.84(1H,s),7.20(1H,d,J=8.6Hz),7.41-7.50(1H,m),7.66-7.70(1H,m),7.76(1H,d,J=2.4Hz),8.00(2H,d,J=6.2Hz),8.00-8.04(1H,m),8.50-8.54(1H,m),8.69(2H,d,J=6.1Hz),8.85(1H,d,J=2.0Hz) | 456 |
B257 | (DMSO):2.99(1H,dd,J=10.8,12.9Hz),3.10-3.21(1H,m),3.46(3H,s),3.66-3.77(2H,m),3.87-3.95(1H,m),4.08(1H,d,J=11.7Hz),4.76(1H,d,J=8.4Hz),6.85(1H,s),7.28-7.33(1H,m),7.41-7.56(2H,m),7.96(2H,d,J=6.0Hz),8.69(2H,d,J=6.0Hz) | 385 |
B258 | (DMSO):2.99(1H,dd,J=10.7,12.6Hz),3.13-3.22(1H,m),3.46(3H,s),3.67-3.77(2H,m),3.87-3.95(1H,m),4.08(1H,d,J=11.5Hz),4.76(1H,d,J=9.2Hz),6.86(1H,s),7.41(1H,t,J=8.6Hz),7.48-7.54(1H,m),7.72-7.81(1H,m),7.98(2H,d,J=5.9Hz),8.69(2H,d,J=5.9Hz) | 445 |
B259 | (DMSO-d6):1.23(6H,d,J=5.9Hz),2.7-2.9(1H,m),3.1-3.3(1H,m),3.47(3H,s),3.6-3.7(1H,m),3.7-4.0(2H,m),3.78(3H,s),4.0-4.1(1H,m),4.4-4.6(1H,m),4.9-5.0(1H,m),6.8-7.0(4H,m),8.00(2H,d,J=5.3Hz),8.69(2H,d,J=5.6Hz) | 437 |
B260 | (DMSO-d6):2.17(3H,s),2.22(3H,s),2.7-2.8(1H,m),3.1-3.2(1H,m),3.46(3H,s),3.6-3.7(1H,m),3.7-3.9(2H,m),3.79(3H,s),4.0-4.1(1H,m),6.84(2H,s),7.19(1H,s),7.99(2H,d,J=5.0Hz),8.69(2H,d,J=4.7Hz) | 407 |
B261 | (DMSO-d6):1.27(6H,d,J=5.1Hz),2.7-2.9(1H,m),3.1-3.3(1H,m),3.46(3H,s),3.6-4.0(3H,m),3.84(3H,s),4.0-4.1(1H,m),4.6-4.7(1H,m),4.9-5.0(1H,m),6.5-6.6(2H,m),6.84(1H,s),7.2-7.3(1H,m),7.99(2H,d,J=6.0Hz),8.69(2H,d,J=6.0Hz) | 437 |
B262 | (DMSO-d6):2.7-2.9(1H,m),3.2-3.3(1H,m),3.47(3H,s),3.6-3.7(1H,m),3.8-4.0(5H,m),4.1-4.2(1H,m),5.0-5.1(1H,m),6.86(1H,s),7.26(1H,d,J=8.5Hz),7.78(1H,s),7.84(1H,d,J=8.5Hz),8.00(2H,d,J=5.7Hz),8.70(2H,d,J=5.6Hz) | 404 |
B263 | (CDCl3):1.40(3H,t,J=6.9Hz),3.38-3.47(3H,m),3.86(6H,s),3.91-4.17(5H,m),5.44(1H,dd,J=10.8,2.1Hz),6.60(1H,d,J=8.4Hz),6.67(1H,s),7.24-7.30(2H,m),7.84(2H,d,J=6.0Hz),8.70(2H,d,J=6.0Hz). | 423 |
B264 | (CDCl3):0.95(3H,t,J=7.2Hz),1.77-1.86(2H,m),3.34-3.47(2H,m),3.89(6H,s),3.92-4.48(5H,m),5.44(1H,d,J=8.4Hz),6.60(1H,d,J=8.4Hz),6.67(1H,s),7.24-7.30(2H,m),7.84(2H,d,J=6.0Hz),8.70(2H,d,J=6.0Hz). | 437 |
B265 | (DMSO-d6):1.30(3H,t,J=6.6Hz),2.97-4.10(8H,m),4.78(1H,d,J=9.6Hz),7.08(1H,s),7.19-7.25(2H,m),7.48-7.54(2H,m),8.35(2H,d,J=6.0Hz),8.88(2H,d,J=6.0Hz). | 381 |
B266 | (DMSO-d6):0.88(3H,t,J=7.2Hz),1.69-1.77(2H,m),1.26(1H,m),3.00-3.26(2H,m),3.59(2H,m),3.88-4.12(3H,m),4.78(1H,d,J=9.6Hz),7.08(1H,s),7.20-7.26(2H,m),7.49-7.54(2H,m),8.36(2H,d,J=6.0Hz),8.90(2H,d,J=6.0Hz). | 395 |
B267 | (CDCl3):0.39-0.43(2H,m),0.53-0.58(2H,m),1.26(1H,m),3.09(1H,dd,J=12.6,10.8Hz),3.29-3.51(3H,m),3.92(1H,m),3.61(3H,s),3.77(1H,m),3.85(3H,s),3.99(1H,m),4.21(1H,m),5.01(1H,dd,J=9.9,1.8Hz),6.63(1H,dd,J=10.8,2.4Hz),6.69(1H,s),6.72(1H,m),7.48(1H,dd,J=8.4,6.9Hz),7.82(2H,dd,J=4.8,1.8Hz),8.71(2H,dd,J=4.8,1.8Hz). | 407 |
B268 | (CDCl3):3.3-3.4(1H,m),3.5-3.6(2H,m),3.59(3H,s),3.83(3H,s),3.9-4.1(2H,m),4.1-4.2(1H,m),4.96(1H,dd,J=2.4,10.2Hz),6.50(1H,s),6.73(1H,s),6.9-7.1(1H,m),7.2-7.3(2H,m),7.81(2H,dd,J=1.5,4.5Hz),8.74(2H,dd,J=1.2,4.5Hz) | 420 |
B269 | (DMSO-d6):2.78(1H,dd,J=10.2,12.8Hz),3.1-3.3(1H,m),3.47(3H,s),3.6-3.7(1H,m),3.8-4.0(5H,m),4.0-4.1(1H,m),4.9-5.0(1H,m),6.84(1H,s),7.06(1H,dd,J=2.0,8.2Hz),7.13(1H,d,J=2.0Hz),7.44(1H,d,J=8.2Hz),7.99(2H,dd,J=1.6,4.7Hz),8.69(2H,dd,J=1.6,4.7Hz) | 413 |
B270 | (DMSO-d6):3.1-3.3(1H,m),3.42(3H,s),3.5-3.6(1H,m),3.6-3.7(2H,m),3.7-3.9(1H,m),3.86(3H,s),3.9-4.0(1H,m),5.1-5.2(1H,m),6.8-7.0(3H,m),7.9-8.0(2H,m),8.6-8.7(2H,m) | 415 |
B271 | (CDCl3):3.3-3.51H,m),3.5-3.7(2H,m),3.61(3H,s),3.9-4.3(3H,m),5.35(1H,dd,J=2.8,9.8Hz),6.73(1H,s),7.3-7.4(1H,m),7.6-7.7(2H,m),7.80(2H,dd,J=1.5,4.7Hz),7.96(1H,d,J=8.1Hz),8.71(2H,dd,J=1.5,4.7Hz) | 390 |
B272 | (DMSO-d6):2.7-2.8(1H,m),3.2-3.3(1H,m),3.47(3H,s),3.6-3.7(1H,m),3.8-4.0(5H,m),4.1-4.2(1H,m),5.0-5.1(1H,m),6.84(1H,s),7.48(1H,d,J=8.1Hz),7.54(1H,s),7.62(1H,d,J=8.1Hz),7.99(2H,dd,J=1.2,4.5Hz),8.70(2H,d,J=1.2,4.5Hz) | 404 |
B273 | (DMSO-d6):2.8-2.9(1H,m),3.1-3.3(1H,m),3.49(3H,s),3.6-3.8(1H,m),3.8-4.0(5H,m),4.1-4.2(1H,m),5.0-5.1(1H,m),6.86(1H,s),7.2-7.6(5H,m),7.72(2H,d,J=7.5Hz),8.01(2H,d,J=6.3Hz),8.70(2H,d,J=6.0Hz) | 455 |
B274 | (CDCl3):1.9-2.1(4H,m),2.83(1H,dd,J=10.2,12.6Hz),3.2-3.5(5H,m),3.5-3.7(1H,m),3.62(3H,s),3.79(3H,s),3.8-3.9(1H,m),3.9-4.1(1H,m),4.2-4.3(1H,m),5.0-5.1(1H,m),6.49(1H,dd,J=3.0,9.0Hz),6.68(1H,s),6.8-6.9(2H,m),7.82(2H,d,J=6.0Hz),8.71(2H,d,J=6.0Hz) | 448 |
B275 | (CDCl3):1.9-2.1(4H,m),2.89(1H,dd,J=10.3,12.8Hz),3.2-3.4(5H,m),3.5-3.6(1H,m),3.60(3H,s),3.75(3H,s),3.7-3.8(1H,m),3.9-4.1(1H,m),4.1-4.3(1H,m),4.99(1H,dd,J=2.1,10.2Hz),6.08(1H,d,J=2.1Hz),6.21(1H,dd,J=2.0,8.5Hz),6.68(1H,s),7.31(1H,d,J=8.5Hz),7.82(2H,dd,J=1.6,4.6Hz),8.71(2H,dd,J=1.6,4.6Hz) | 448 |
B276 | (DMSO):2.84(1H,dd,J=10.5,12.8Hz),3.19-3.26(1H,m),3.49(3H,s),3.66(1H,d,J=12.7Hz),3.88-3.94(2H,m),3.90(3H,s),4.12(1H,d,J=10.3Hz),5.06(1H,d,J=9.2Hz),6.85(1H,s),7.17(1H,d,J=8.6Hz),7.26-7.33(2H,m),7.36-7.40(1H,m),7.48-7.53(2H,m),7.63(1H,s),8.01(2H,d,J=5.7Hz),8.69(2H,d,J=5.6Hz) | 473 |
B277 | (DMSO):2.90(1H,dd,J=10.3,12.8Hz),3.26-3.29(1H,m),3.49(3H,s),3.67(1H,d,J=13.1Hz),3.82(3H,s),3.85-3.94(2H,m),3.89(3H,s),4.14(1H,d,J=9.6Hz),5.06(1H,d,J=8.7Hz),6.85(1H,s),6.90-6.93(1H,m),7.12-7.19(3H,m),7.34-7.39(1H,m),7.60-7.64(1H,m),7.71(1H,d,J=2.1Hz),8.01(2H,d,J=6.0Hz),8.69(2H,d,J=5.9Hz) | 485 |
B278 | (DMSO):2.84(1H,dd,J=10.5,12.6Hz),3.18-3.25(1H,m),3.48(3H,s),3.66(1H,d,J=13.2Hz),3.86-3.93(2H,m),3.90(3H,s),4.10(1H,d,J=10.2Hz),5.07(1H,d,J=9.0Hz),6.85(1H,s),7.16(1H,d,J=8.7Hz),7.39-7.45(2H,m),7.50-7.52(2H,m),7.72(1H,d,J=1.8Hz),8.01(2H,d,J=5.4Hz),8.70(2H,d,J=5.4Hz) | 523 |
B279 | (DMSO):1.52-1.71(4H,m),2.32-2.43(4H,m),2.76(1H,dd,J=10.2,12.9Hz),3.18-3.25(1H,m),3.47(3H,s),3.54(2H,d,J=3.9Hz),3.65(1H,d,J=12.9Hz),3.81-3.91(2H,m),3.82(3H,s),4.10(1H,d,J=9.9Hz),4.99(1H,d,J=8.7Hz),6.84(1H,s),6.97(1H,d,J=8.4Hz),7.17-7.23(1H,m),7.39(1H,d,J=1.8Hz),8.00(2H,d,J=6.0Hz),8.69(2H,d,J=6.0Hz) | 462 |
B280 | (DMSO):3.11(1H,dd,J=10.3,12.6Hz),3.41-3.48(1H,m),3.67(3H,s),3.86(1H,d,J=12.7Hz),4.03-4.13(2H,m),4.08(3H,s),4.32(1H,d,J=11.0Hz),5.25(1H,d,J=8.6Hz),7.04(1H,s),7.33-7.36(2H,m),7.60-7.70(3H,m),7.86(1H,dd,J=2.4,8.5Hz),7.93(1H,d,J=2.3Hz),8.19(2H,d,J=6.1Hz),8.88(2H,d,J=6.0Hz) | 473 |
B281 | (DMSO):2.83(1H,dd,J=10.2,12.9Hz),3.14-3.25(1H,m),3.49(3H,s),3.66(1H,d,J=12.6Hz),3.76(3H,s),3.84-3.93(2H,m),3.87(3H,s),4.10(1H,d,J=11.4Hz),5.04(1H,d,J=8.7Hz),6.85(1H,s),6.98-7.03(1H,m),7.07-7.11(2H,m),7.25-7.34(2H,m),7.41-7.47(1H,m),7.53(1H,d,J=2.4Hz),8.01(2H,d,J=6.3Hz),8.70(2H,d,J=6.0Hz) | 485 |
B282 | (DMSO):2.88(1H,dd,J=10.3,12.9Hz),3.18-3.28(1H,m),3.48(3H,s),3.67(1H,d,J=12.8Hz),3.79(3H,s),3.85-3.94(2H,m),3.87(3H,s),4.13(1H,d,J=11.6Hz),5.05(1H,d,J=8.4Hz),6.85(1H,s),7.01(1H,d,J=8.8Hz),7.11(1H,d,J=8.7Hz),7.53-7.56(3H,m),7.66(1H,d,J=2.3Hz),8.00(2H,d,J=6.1Hz),8.69(2H,d,J=6.0Hz) | 485 |
B283 | (DMSO):2.77(1H,dd,J=10.2,12.8Hz),3.10-3.21(1H,m),3.47(3H,s),3.65(1H,d,J=12.9Hz),3.80(3H,s),3.84-3.92(2H,m),4.04-4.10(1H,m),4.98(1H,d,J=8.4Hz),6.68-6.73(1H,m),6.85(1H,s),6.92-6.98(3H,m),7.01-7.08(1H,m),7.14-7.20(2H,m),7.23(1H,d,J=2.6Hz),7.94(1H,s),8.01(2H,d,J=6.1Hz),8.69(2H,d,J=6.1Hz) | 470 |
B284 | (CDCl3):3.37-3.54(3H,m),3.59(3H,s),3.88(1H,m),4.03(1H,m),4.18(1H,m),4.99(1H,dd,J=10.2,2.4Hz),6.73(1H,s),6.78(1H,s),7.25-7.33(2H,m),7.49-7.58(2H,m),7.81(2H,dd,J=4.5,1.8Hz),8.72(dd,J=4.5,1.8Hz). | 389 |
B285 | (CDCl3):2.80(1H,dd,J=12.9,10.2Hz),3.35(1H,m),3.55(1H,m),3.61(3H,s),3.77(1H,m),3.85(3H,s),3.99(1H,m),4.21(1H,m),5.01(1H,dd,J=9.9,1.8Hz),6.63(1H,dd,J=10.8,2.4Hz),6.69(1H,s),6.72(1H,m),7.48(1H,dd,J=8.4,6.9Hz),7.82(2H,dd,J=4.8,1.8Hz),8.71(2H,dd,J=4.8,1.8Hz). | 397 |
B286 | (CDCl3):3.33-3.53(3H,m),3.58(3H,s),3.88(1H,m),3.98(1H,m),4.01(3H,s),4.18(1H,m),5.00(1H,m),6.72(1H,s),6.77(1H,s),6.82(1H,m),7.16-7.19(2H,m),7.83(2H,d,J=6.0Hz),8.72(2H,d,J=6.0Hz). | 419 |
B287 | (DMSO-d6):1.9-2.1(4H,m),2.9-3.2(3H,m),3.2-3.5(3H,m),3.51(3H,s),3.72(1H,d,J=11.7Hz),3.90(3H,s),3.8-4.1(2H,m),4.14(1H,d,J=12.9Hz),4.41(2H,d,J=5.4Hz),5.08(1H,d,J=9.6Hz),7.08(1H,s),7.18(1H,d,J=8.7Hz),7.4-7.6(1H,m),7.6-7.8(2H,m),7.79(1H,s),7.96(1H,s),8.46(2H,d,J=6.0Hz),8.93(2H,d,J=5.4Hz),11.5(1H,brd) | 538 |
B288 | (CDCl3):1.9-2.1(4H,m),3.17(1H,dd,J=10.5,12.9Hz),3.3-3.4(5H,m),3.5-3.6(1H,m),3.57(3H,s),3.7-3.8(1H,m),3.9-4.1(1H,m),4.1-4.2(1H,m),4.69(1H,dd,J=2.1,10.5Hz),6.73(1H,s),6.54(1H,m),6.60(1H,d,J=1.2Hz),6.6-6.7(2H,m),7.2-7.3(1H,m)7.81(2H,dd,J=1.5,4.5Hz),8.71(2H,dd,J=1.8,4.5Hz) | 418 |
B289 | (CDCl3):1.9-2.1(4H,m),3.17(1H,dd,J=10.5,12.9Hz),3.3-3.4(5H,m),3.5-3.6(1H,m),3.57(3H,s),3.7-3.8(1H,m),3.9-4.1(1H,m),4.1-4.2(1H,m),4.69(1H,dd,J=2.1,10.5Hz),6.73(1H,s),6.54(1H,m),6.60(1H,d,J=1.2Hz),6.6-6.7(2H,m),7.2-7.3(1H,m)7.81(2H,dd,J=1.5,4.5Hz),8.71(2H,dd,J=1.8,4.5Hz) | 418 |
B290 | (CDCl3):2.87(1H,m),3.38(1H,m),3.58(1H,m),3.64(3H,s),3.84(1H,m),3.91(3H,s),4.03(1H,m),4.22(1H,m),5.11(1H,m),6.70(1H,s),7.08-7.46(6H,m),7.60(1H,d,J=5.1Hz),7.83(2H,d,J=6.0Hz),8.72(2H,d,J=6.0Hz). | 473 |
B291 | (CDCl3):2.86(1H,dd,J=12.9,10.2Hz),3.38(1H,m),3.57(1H,m),3.64(3H,s),3.88(1H,m),3.93(3H,s),4.02(1H,m),4.26(1H,m),5.10(1H,m),6.70(1H,s),7.05-7.07(2H,m),7.21-7.42(4H,m),7.60(1H,d,J=4.8Hz),7.83(2H,dd,J=4.5,1.2Hz),8.72(2H,dd,J=4.5,1.2Hz). | 473 |
B292 | (CDCl3):2.86(1H,dd,J=12.9,10.2Hz),3.35(1H,m),3.57(1H,m),3.64(3H,s),3.88(1H,m),3.93(3H,s),4.02(1H,m),4.22(1H,m),5.10(1H,m),6.70(1H,s),7.04(1H,s),7.10-7.23(3H,m),7.52-7.60(3H,m),7.83(2H,d,J=6.0Hz),8.72(2H,d,J=6.0Hz). | 473 |
B293 | (DMSO):2.86(1H,dd,J=10.2,12.8Hz),3.22-3.30(1H,m),3.49(3H,S),3.68(1H,d,J=12.1Hz),3.87-3.96(2H,m),3.91(3H,s),4.16(1H,d,J=11.9Hz),5.07(1H,d,J=8.7Hz),6.85(1H,s),7.16(1H,d,J=8.7Hz),7.27-7.32(1H,m),7.81-7.94(2H,m),7.99-8.05(3H,m),8.26(1H,d,J=2.3Hz),8.63-8.65(1H,m),8.69(2H,d,J=6.0Hz) | 456 |
B294 | (DMSO):2.90(1H,dd,J=10.5,12.9Hz),3.20-3.29(1H,m),3.49(3H,s),3.68(1H,d,J=12.3Hz),3.84-3.92(2H,m),3.91(3H,s),3.95(3H,s),4.15(1H,d,J=12.0Hz),5.07(1H,d,J=9.0Hz),6.73(1H,d,J=8.1Hz),6.85(1H,s),7.17(1H,d,J=8.7Hz),7.48(1H,d,J=7.5Hz),7.76(1H,t,J=7.8Hz),8.01(2H,d,J=6.0Hz),8.07(1H,dd,J=2.1,8.7Hz),8.15(1H,d,J=2.1Hz),8.69(1H,d,J=6.0Hz) | 486 |
B295 | (DMSO):2.91(1H,dd,J=10.2,12.8Hz),3.21-3.28(1H,m),3.48(3H,s),3.67(1H,d,J=12.5Hz),3.84-3.94(2H,m),3.88(3H,s),3.89(3H,s),4.12(1H,d,J=9.9Hz),5.06(1H,d,J=8.5Hz),6.85(1H,s),6.90(1H,d,J=8.7Hz),7.15(1H,d,J=8.6Hz),7.58-7.63(1H,m),7.67(1H,d,J=2.4Hz,),7.94-7.98(1H,m),8.01(2H,d,J=6.1Hz),8.42(1H,d,J=2.3Hz),8.69(2H,d,J=6.2Hz) | 486 |
B296 | (DMSO):2.84(1H,dd,J=10.5,12.6Hz),3.18-3.25(1H,m),3.48(3H,s),3.62(1H,d,J=13.2Hz),3.85-3.99(2H,m),3.87(3H,s),3.94(6H,s),4.11(1H,d,J=10.2Hz),5.04(1H,d,J=9.6Hz),6.85(1H,s),7.12(1H,d,J=8.7Hz),7.46(1H,d,J=8.4Hz),7.56(1H,s),8.00(2H,d,J=4.8Hz),8.32(1H,s),8.70(2H,d,J=5.1Hz) | 487 |
B297 | (CDCl3):2.2-2.4(1H,m),2.4-2.6(1H,m),3.3-3.4(1H,m),3.5-3.8(3H,m),3.58(3H,s),3.9-4.1(1H,m),4.1-4.3(2H,m),4.5-4.6(1H,m),6.71(1H,s),6.87(1H,d,J=8.4Hz),7.00(1H,t,J=7.8Hz),7.25(1H,t,J=8.4Hz),7.62(1H,dd,J=1.5,8.1Hz),7.78(2H,dd,J=1.5,4.5Hz),8.71(2H,dd,J=1.8,6.6Hz) | 391 |
B298 | (CDCl3):1.8-2.0(3H,m),2.3-2.4(1H,m),3.2-3.4(1H,m),3.44(3H,s)3.5-3.6(1H,m),3.7-3.9(3H,m),4.1-4.2(1H,m),4.2-4.4(2H,m),6.66(1H,s),7.02(1H,dd,J=1.2,8.1Hz),7.14(1H,t,J=7.2Hz),7.22(1H,dd,J=1.8,7.5Hz),7.59(1H,dd,J=1.8,7.8Hz),7.79(2H,dd,J=1.5,4.5Hz),8.71(2H,dd,J=1.5,4.5Hz) | 405 |
C001 | (CDCl3):1.79-1.95(m,3H),2.14(m,1H),3.08(m,1H),3.26(dd,J=12.6,7.2Hz,1H),3.53(s,3H),3.65(m,1H),3.82-3.96(m,2H),6.65(s,1H),7.47(t,J=7.8Hz,2H),7.61(t,J=7.5Hz,1H),7.79(d,J=6.0Hz,2H),8.02(d,J=7.5Hz,2H),8.70(d,J=6.0Hz,2H). | 374 |
C002 | (CDCl3):1.81-1.92(m,3H),2.12(m,1H),3.08(m,1H),3.25(m,1H),3.52(s,3H),3.64(m,1H),3.75-3.92(m,2H),6.65(s,1H),7.12(t,J=8.4Hz,2H),7.84(m,1H),8.03(dd,J=7.8,5.7Hz,2H),8.76(m,1H). | 392 |
C005 | (CDCl3):1.65-1.93(m,3H),2.13(m,1H),3.08(m,1H),3.25(dd,J=12.9,10.5Hz,1H),3.53(s,3H),3.65(m,1H),3.88(s,3H),3.77-3.94(m,2H),6.65(s,1H),6.93(dd,J=9.6,1.2Hz,2H),7.80(d,J=6.0Hz,2H),8.00(dd,J=9.9,1.2Hz,2H),8.70(d,J=6.0Hz,2H). | 405 |
C006 | (CDCl3):1.69-1.92(m,3H),2.12(m,1H),3.06(m,1H),3.21(dd,J=12.9,10.2Hz,1H),3.50(s,3H),3.60-3.83(m,3H),3.86(s,3H),6.66(s,1H),6.96-7.05(m,2H),7.45-7.57(m,2H),7.79(d,J=4.5Hz,2H),8.69(d,J=4.8Hz,2H). | 405 |
C067 | (CDCl3):1.83-2.14(m,4H),2.77(m,1H),3.06(m,1H),3.37(m,1H),3.45(s,3H),3.58(m,1H),3.90(m,1H),6.64(s,1H),7.13(m,1H),7.33(m,2H),7.53(d,J=8.2Hz,2H),7.64(m,1H),7.79(d,J=5.8Hz,2H),8.70(d,J=5.7Hz,2H). | 390 |
C091 | (CDCl3):1.81-2.01(6H,m),2.70-2.75(2H,m),3.00(1H,m),3.25-3.92(6H,m),3.35(3H,s),6.61(1H,s),7.12-7.26(4H,m),7.72(2H,d,J=6.0Hz),8.69(2H,d,J=6.0Hz). | 430 |
C092 | (DMSO-d6):1.48-1.89(m,10H),2.92-3.07(m,4H),3.41(s,3H),3.42-3.72(m,5H),6.97(s,1H),8.38(d,J=5.1Hz,2H),8.92(d,J=5.1Hz,2H). | 382 |
C094 | (CDCl3):1.74-2.05(m,4H),3.08(m,2H),3.28(m,1H),3.51(s,3H),3.59-3.80(m,10H),6.63(s,1H),7.76(d,J=4.8Hz,2H),8.71(d,J=4.8Hz,2H). | 384 |
C101 | (CDCl3):3.37-3.50(m,3H),3.57(s,3H),3.90-4.00(m,2H),4.10-4.19(m,1H),5.14(dd,J=2.7,9.3Hz,1H),6.70(s,1H),7.48(t,J=7.8Hz,2H),7.63(t,J=7.5Hz,1H),7.79(dd,J=1.5,4.8Hz,2H),8.06(dd,J=1.2,7.2Hz,2H),8.73(dd,J=1.8,6.3Hz,2H). | 377 |
C102 | (CDCl3):3.30-3.50(m,3H),3.58(s,3H),3.85-4.17(m,3H),5.04(dd,J=2.7,9.3Hz,1H),6.07(s,1H),7.14(dd,J=7.2,8.7Hz,2H),7.78(dd,J=1.5,4.8Hz,2H),8.11(m,2H),8.73(dd,J=1.5,4.5Hz,2H). | 395 |
C105 | (CDCl3):1.65-1.93(3H,m),2.13(1H,m),3.08(1H,m),3.25(1H,dd,J=12.9,10.5Hz),3.53(3H,s),3.65(1H,m),3.88(3H,s),3.77-3.94(2H,m),6.65(1H,s),6.93(2H,dd,J=9.6,1.2Hz),7.80(2H,d,J=6.0Hz),8.00(2H,dd,J=9.9,1.2Hz),8.70(2H,d,J=6.0Hz). | 405 |
C106 | (CDCl3):1.69-1.92(3H,m),2.12(1H,m),3.06(1H,m),3.21(1H,dd,J=12.9,10.2Hz),3.50(3H,s),3.60-3.83(3H,m),3.86(3H,s),6.66(1H,s),6.96-7.05(2H,m),7.45-7.57(2H,m),7.79(2H,d,J=4.5Hz),8.69(2H,d,J=4.8Hz). | 405 |
C386 | (CDCl3):1.80-2.11(4H,m),3.07(1H,m),3.26(1H,dd,J=13.1,10.7Hz),3.53(3H,s),3.59-3.66(2H,m),3.88(1H,m),6.65(1H,s),6.95(1H,d,J=4.2Hz),7.62(1H,d,J=4.2Hz),7.78(2H,dd,J=4.5,1.6Hz),8.71(2H,dd,J=4.5,1.6Hz). | 415 |
C389 | (CDCl3):3.3-3.7(3H,m),3.57(3H,s),3.9-4.0(2H,m),4.1-4.2(1H,m),5.14(1H,dd,J=2.1,9.0Hz),6.70(1H,s),7.4-7.5(2H,m),7.6-7.7(1H,m),7.78(2H,dd,J=1.2,4.5Hz),8.05(2H,dd,J=1.2,7.2Hz),8.73(2H,dd,J=0.9,4.5Hz) | 377 |
C390 | (CDCl3):3.3-3.7(3H,m),3.57(3H,s),3.9-4.0(2H,m),4.1-4.2(1H,m),5.14(1H,dd,J=2.1,9.0Hz),6.70(1H,s),7.4-7.5(2H,m),7.6-7.7(1H,m),7.78(2H,dd,J=1.2,4.5Hz),8.05(2H,dd,J=1.2,7.2Hz),8.73(2H,dd,J=0.9,4.5Hz) | 377 |
D001 | (CDCl3):2.01-2.10(m,4H),3.16(m,2H),3.56(s+m,3H+1H),3.76(m,2H),6.69(s,1H),7.53(m,2H),7.63(m,1H),7.83(d,J=6.0Hz,2H),8.50(d,J=7.2Hz,2H),8.73(d,J=6.0Hz,2H). | 375 |
D002 | (CDCl3):1.93(m,2H),2.12(m,2H),3.12(m,2H),3.42(m,1H),3.53(s,3H),3.71(m,2H),6.68(s,1H),7.17(m,1H),7.28(m,1H),7.56(m,1H),7.80-7.86(m,3H),8.71(d,J=6.0Hz,2H). | 393 |
D003 | (CDCl3):1.94-2.10(m,4H),3.15(m,2H),3.49(m,1H),3.55(s,3H),3.75(m,2H),6.69(s,1H),7.31(m,1H),7.50(m,1H),7.65(m,1H),7.76(d,J=7.8Hz,1H),7.82(d,J=6.0Hz,2H),8.72(d,J=6.0Hz,2H). | 393 |
D004 | (CDCl3):1.95-2.06(m,4H),3.14(m,2H),3.50(m,1H),3.55(s,3H),3.75(m,2H),6.69(s,1H),7.19(t,J=8.6Hz,2H),7.82(d,J=6.0Hz,2H),8.02(m,2H),8.71(d,J=6.0Hz,2H). | 393 |
D005 | (CDCl3):1.89(m,2H),2.08(m,2H),3.06(m,2H),3.50(m,1H),3.53(s,3H),3.67(m,2H),3.93(s,3H),6.66(s,1H),6.98-7.06(m,2H),7.49(m,1H),7.61(m,1H),7.81(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 405 |
D006 | (CDCl3):1.94-2.10(m,4H),3.14(m,2H),3.50(m,1H),3.54(s,3H),3.74(m,2H),3.88(s,3H),6.68(s,1H),7.15(m,1H),7.39-7.57(m,3H),7.82(d,J=6.3Hz,2H),8.71(d,J=6.3Hz,2H). | 405 |
D007 | (CDCl3):1.99-2.06(m,4H),3.13(m,2H),3.50(m,1H),3.55(s,3H),3.75(m,2H),3.90(s,3H),6.68(s,1H),6.99(d,J=9.0Hz,2H),7.82(d,J=6.0Hz,2H),7.98(d,J=9.0Hz,2H),8.71(d,J=6.0Hz,2H). | 405 |
D008 | (CDCl3):1.94-2.06(m,4H),3.15(m,2H),3.49(m,1H),3.54(s,3H),3.75(m,2H),6.69(s,1H),7.44-7.60(m,2H),7.81-7.93(m,3H),7.94(s,1H),8.71(d,J=5.7Hz,2H). | 409 |
D009 | (CDCl3):1.94-2.06(m,4H),3.13(m,2H),3.49(m,1H),3.54(s,3H),3.74(m,2H),6.69(s,1H),7.49(d,J=8.4Hz,2H),7.81(d,J=6.0Hz,2H),7.92(d,J=8.4Hz,2H),8.71(d,J=6.0Hz,2H). | 409 |
D0010 | (CDCl3):1.95-2.06(m,4H),3.13(m,2H),3.48(m,1H),3.54(s,3H),3.74(m,2H),6.68(s,1H),7.66(d,J=8.4Hz,2H),7.80-7.86(m,4H),8.71(d,J=6.0Hz,2H). | 454 |
D011 | (CDCl3):1.89(m,2H),2.08(m,2H),3.06(m,2H),3.38(m,1H),3.52(s,3H),3.67(m,2H),3.91(s,3H),3.92(s,3H),6.66(s,1H),7.02-7.16(m,3H),7.80(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 435 |
D012 | (CDCl3):1.93(m,2H),2.10(m,2H),3.11(m,2H),3.38(m,1H),3.53(s,3H),3.72(m,2H),6.68(s,1H),6.88-7.04(m,2H),7.81(d,J=5Hz,2H),7.91(m,1H),8.71(d,J=5Hz,2H). | 411 |
D013 | (CDCl3):1.95-2.06(m,4H),3.14(m,2H),3.46(m,1H),3.54(s,3H),3.75(m,2H),6.69(s,1H),7.32(m,1H),7.75-7.86(m,4H),8.71(d,J=5.9Hz,2H). | 411 |
D014 | (CDCl3):2.06-2.08(m,4H),3.12(m,2H),3.38(m,1H),3.55(s,3H),3.76(m,2H),6.69(s,1H),7.19(m,1H),7.71(d,J=5.2Hz,2H),7.79-7.83(m,3H),8.71(d,J=5.6Hz,2H). | 381 |
D015 | (CDCl3):1.95-2.07(m,4H),3.11(m,2H),3.37(m,1H),3.55(s,3H),3.75(m,2H),6.60(m,1H),6.68(s,1H),7.29(m,1H),7.63(s,1H),7.82(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 365 |
D016 | (CDCl3):1.95(m,2H),2.12(m,2H),3.18(m,2H),3.55(s,3H),3.76(m,2H),4.16(m,1H),6.67(s,1H),7.52(m,1H),7.82-7.91(m,3H),8.08(d,J=8.3Hz,1H),8.70-8.72(m,3H). | 376 |
D017 | (CDCl3):2.17-2.28(m,4H),3.16(m,2H),3.31(m,1H),3.57(s,3H),3.80(m,2H),6.70(s,1H),6.72(d,J=3.7Hz,1H),7.28-7.42(m,2H),7.52(d,J=3.7Hz,1H),7.60(d,J=7.7Hz,1H),7.82(d,J=6.0Hz,2H),8.49(d,J=8.1Hz,1H),8.72(d,J=6.0Hz,2H). | 414 |
D018 | (CDCl3):1.83(m,2H),1.95-2.18(m,4H),2.73(t,J=6.5Hz,2H),2.86(m,2H),3.13(m,1H),3.52(s,3H),3.65(m,2H),3.82(t,J=6.8Hz,2H),6.65(s,1H),7.21-7.26(m,4H),7.78(d,J=6.0Hz,2H),8.69(d,J=6.0Hz,2H). | 430 |
D019 | (CDCl3):1.98-2.21(m,4H),2.76(m,1H),3.05(m,2H),3.25(t,J=8.3Hz,2H),3.55(s,3H),3.77(m,2H),4.20(t,J=8.3Hz,2H),6.68(s,1H),7.05(m,1H),7.20-7.27(m,2H),7.82(d,J=5.9Hz,2H),8.26(d,J=8.2Hz,1H),8.71(d,J=5.9Hz,2H). | 416 |
D020 | (CDCl3):1.94-2.18(m,4H),2.81-3.08(m,5H),3.54(s,3H),3.71-3.89(m,4H),4.72-4.77(m,2H),6.67(s,1H),7.19-7.26(m,4H),7.81(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 430 |
D021 | (CDCl3):2.02-2.09(m,4H),3.10(m,2H),3.29(m,1H),3.54(s,3H),3.75(m,2H),6.69(s,1H),7.01(d,J=3.9Hz,1H),7.57(d,J=3.9Hz,1H),7.81(d,J=6.2Hz,2H),8.71(d,J=6.2Hz,2H). | 415 |
D022 | (CDCl3):1.98-2.10(m,4H),3.16(m,2H),3.55(s,3H),3.58(m,1H),3.76(m,2H),6.69(s,1H),7.40-7.52(m,3H),7.64(d,J=7.8Hz,2H),7.73(d,J=8.4Hz,1H),7.82(d,J=6.0Hz,2H),8.06(d,J=8.4Hz,2H),8.72(d,J=6.0Hz,2H). | 451 |
D023 | (CDCl3):1.57-1.77(m,4H),2.30(m,1H),2.59(m,2H),3.43(s,3H),3.49(m,2H),6.62(s,1H),7.35-7.53(m,8H),7.57(m,1H),7.74(d,J=5.9Hz,2H),8.69(d,J=5.9Hz,2H). | 451 |
D024 | (CDCl3):1.97-2.12(m,4H),3.11(m,2H),3.50(m,1H),3.54(s,3H),3.73(m,2H),6.68(s,1H),7.51-7.61(m,3H),7.80-7.82(m,3H),7.92(m,1H),8.02(d,J=8.4Hz,1H),8.34(d,J=7.5Hz,1H),8.71(d,J=6.0Hz,2H). | 425 |
D025 | (CDCl3):1.89(m,2H),2.06(m,2H),3.06(m,2H),3.51(m,1H),3.53(s,3H),3.68(m,2H),3.94(s,3H),6.70(s,1H),6.68-6.78(m,2H),7.70(dd,J=8.7,6.9Hz,1H),7.81(d,J=6.0Hz,2H),8.71(d,J=6.0Hz,2H). | 423 |
试验实施例:本发明药物对经小牛大脑TPK1的P-GS1磷酸化的抑制活性
采用含有100mM MES-氢氧化钠(pH 6.5)、1mM乙酸镁、0.5mM EGTA、5mM β-巯基乙醇、0.02%吐温20、10%甘油、12μg/ml P-GS 1、41.7μM[γ-32P]ATP(68kBq/ml)、小牛大脑TPK1和如表中所示化合物的混合物(由于制备试验化合物的溶液时存在10%的DMSO,最终混合物含有1.7%的DMSO)作为反应体系。通过加入ATP启动磷酸化反应,并且该反应在25℃下进行2小时,然后在冰浴冷却下加入21%高氯酸终止反应。该反应混合物在12,000rpm下离心5分钟冰吸附于P81纸(Whatmann)上,然后该纸以75mM磷酸洗涤4次,水洗涤3次和丙酮洗涤一次。将该纸干燥,并以液体闪烁计数器测定残余物的放射活性。结果如下表所示。试验化合物显著抑制经TPK1的P-GS1磷酸化。该结果显然提示本发明药物抑制了TPK1的活性,进而抑制Aβ的神经毒性和PHF形成,以及本发明药物能够有效预防和/或治疗阿耳茨海默氏病和上面提及的疾病。
制剂实施例
(1)片剂
以常规方法混合下列成分并采用常规设备压片。
实施例1的化合物 30mg
结晶纤维素 60mg
玉米淀粉 100mg
乳糖 200mg
硬脂酸镁 4mg
(2)软胶囊
以常规方法混合下列成分并填充软胶囊。
实施例1的化合物 30mg
橄榄油 300mg
卵磷脂 20mg
工业应用
本发明的化合物具有抑制TPK1的活性并用作药物活性成分以预防和/或治疗由于TPK1活性异常过高所致的疾病如神经变性性疾病(例如阿耳茨海默氏病)和上面提及的疾病。
表3
Compound No. | IC50(nM) |
A001 | 8.9 |
A002 | 27 |
A003 | 25 |
A006 | 13 |
B010 | 6 |
B037 | 4.8 |
B046 | 8.3 |
B051 | 1.9 |
B054 | 4 |
B063 | 6 |
B079 | 3.3 |
B084 | 1.1 |
B085 | 1.4 |
B087 | 5 |
B088 | 6 |
B090 | 1.1 |
B091 | 1.2 |
B093 | 0.28 |
B094 | 1.2 |
B097 | 2.8 |
B100 | 4.7 |
B102 | 0.62 |
B103 | 0.36 |
B104 | 10.6 |
B105 | 1.6 |
B106 | 1.4 |
B107 | 50 |
B108 | 6.7 |
B109 | 7.7 |
B110 | 8.2 |
B112 | 4.7 |
B113 | 4.8 |
B120 | 54 |
B122 | 63 |
B128 | 30 |
B130 | 52.9 |
B140 | 8 |
B143 | 56 |
B184 | 8 |
B185 | 0.67 |
B186 | 1.9 |
B187 | 2 |
B189 | 5 |
B220 | 1.1 |
B217 | 70.3 |
B225 | 64 |
B234 | 30 |
B235 | 26.9 |
B236 | 11 |
B238 | 7.8 |
B239 | 17 |
B240 | 1.2 |
B241 | 0.9 |
B242 | 12 |
B243 | 0.906 |
B244 | 0.3 |
B245 | 0.44 |
B246 | 27 |
B247 | 72 |
B248 | 32 |
B249 | 10 |
B251 | 40 |
B252 | 5.2 |
B253 | 15 |
B254 | 3.9 |
B255 | 21 |
B256 | 1.1 |
B257 | 67 |
B258 | 12 |
B259 | 4.5 |
B260 | 0.76 |
B261 | 1.3 |
B262 | 1.1 |
B263 | 1.2 |
B264 | 15 |
B268 | 13 |
B269 | 1.5 |
B270 | 0.79 |
B271 | 3.2 |
B272 | 0.98 |
B273 | 1.9 |
B274 | 3.4 |
B275 | 2.1 |
B276 | 2.5 |
B277 | 8.1 |
B279 | 1.1 |
B280 | 9.3 |
B281 | 5.5 |
B282 | 17 |
B283 | 3.1 |
B284 | 9.8 |
B285 | 8.9 |
B286 | 17 |
B287 | 0.57 |
B288 | 40 |
B289 | 33 |
B290 | 2 |
B291 | 2 |
B292 | 1.5 |
B293 | 1.8 |
B294 | 1.2 |
B295 | 2.7 |
B296 | 2.5 |
B297 | 23 |
B298 | 94 |
C001 | 2.1 |
C002 | 8.4 |
C005 | 45 |
C006 | 9 |
C067 | 72 |
C091 | 23 |
C092 | 63 |
C101 | 3.5 |
C102 | 20.4 |
C105 | 45 |
C106 | 9 |
C386 | 10 |
C389 | 34 |
C390 | 1.0 |
D001 | 9 |
D002 | 23 |
D004 | 15 |
D007 | 18 |
D009 | 6 |
D011 | 11 |
D012 | 19 |
D013 | 19 |
D014 | 20 |
D017 | 10 |
D018 | 4.3 |
D019 | 8.1 |
D021 | 11 |
D022 | 7.8 |
D023 | 13 |
D024 | 19 |
D025 | 16 |
Claims (18)
1、一种式(I)代表的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物:
其中R1代表可被取代的C1-C12烷基;
R代表下式IV或V中的任一基团:
R9和R10代表可被取代的C1-C8烷基、可被取代的C3-C8环烷基、可被取代的苯环、可被取代的萘环、具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环,或者R9和R10代表-N(R11)(R12),其中R11代表氢原子、C1-C8烷基;并且R12代表C1-C8烷基、可被取代的苯环、可被取代的萘环、或者具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的任选取代的杂环;
并且X代表CH2、O或NR13,其中R13代表氢原子或C1-C8烷基。
2、如权利要求1的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R1是甲基。
3、如权利要求1或2的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R是式(IV)代表的基团。
4、如权利要求3的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R9是可被取代的苯环。
5、如权利要求3的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中X是CH2。
6、如权利要求3的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中X是O。
7、一种嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,所述嘧啶酮衍生物选自:
2-[3-(4-氟苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-(3-苯甲酰基哌啶-1-基)-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[3-(2-甲氧基苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[3-(4-甲氧基苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-氟苯甲酰基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-(2-苯甲酰基吗啉-4-基)-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(2-甲氧基苯甲酰基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[2-(4-甲氧基苯甲酰基)吗啉-4-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮。
8、如权利要求1或2的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R是式(V)代表的基团。
9、如权利要求8的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R10是可被取代的苯环。
10、如权利要求8的嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,其中R10是具有1-4个选自氧原子、硫原子和氮原子的杂原子且总共具有5-10个构成环的原子的杂环。
11、一种嘧啶酮衍生物或其盐、或其溶剂化物或其水合物,所述嘧啶酮衍生物选自:
2-[4-(4-氯苯甲酰基)哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[4-(3,4-二氢-2H-喹啉-1-羰基)-哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮;
2-[4-(2,3-二氢吲哚-1-羰基)-哌啶-1-基]-3-甲基-6-吡啶-4-基-3H-嘧啶-4-酮。
12、一种药物,包括以选自如权利要求1的式(I)代表的嘧啶酮衍生物及其盐、以及其溶剂化物和其水合物作为活性成分。
13、一种τ蛋白激酶1抑制剂,选自如权利要求1的式(I)代表的嘧啶酮衍生物及其盐、以及其溶剂化物和其水合物。
14、如权利要求12的药物,其用于预防和/或治疗由τ蛋白激酶1活性过高引起的疾病。
15、如权利要求12的药物,其用于预防和/或治疗神经变性疾病。
16、如权利要求15的药物,其中疾病选自阿耳茨海默氏病、缺血性脑血管意外、特瓦综合症、大脑淀粉样疾病所致的大脑出血、进行性核上性麻痹、亚急性硬化性全脑炎的帕金森病、脑炎后帕金森病、拳击性脑炎、关岛帕金森病-痴呆综合症、勒尾小体病、皮克氏病、皮质延髓退化、额颞性痴呆、血管性痴呆、跌打损伤、脑和脊髓外伤、周围神经病、视网膜病和青光眼。
17、如权利要求14的药物,其中疾病选自:非胰岛素依赖性糖尿病、肥胖症、躁狂抑郁疾病、精神分裂症、秃发症、乳癌、非小细胞肺癌、甲状腺癌、T或B-细胞白血病、和病毒诱发的肿瘤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP331675/2001 | 2001-09-21 | ||
JP2001331674 | 2001-09-21 | ||
JP331677/2001 | 2001-09-21 | ||
JP331678/2001 | 2001-09-21 | ||
JP331674/2001 | 2001-09-21 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028184696A Division CN100488958C (zh) | 2001-09-21 | 2002-09-20 | 3-取代的-4-嘧啶酮衍生物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101274928A true CN101274928A (zh) | 2008-10-01 |
Family
ID=34685721
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008100076698A Pending CN101274928A (zh) | 2001-09-21 | 2002-09-20 | 3-取代的-4-嘧啶酮衍生物 |
CN 200510097948 Expired - Fee Related CN1810802B (zh) | 2001-09-21 | 2002-09-20 | 3-取代的-4-嘧啶酮衍生物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510097948 Expired - Fee Related CN1810802B (zh) | 2001-09-21 | 2002-09-20 | 3-取代的-4-嘧啶酮衍生物 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN101274928A (zh) |
ZA (2) | ZA200401850B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5300477A (en) * | 1992-07-17 | 1994-04-05 | Rohm And Haas Company | 2-arylpyrimidines and herbicidal use thereof |
TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
-
2002
- 2002-09-20 CN CNA2008100076698A patent/CN101274928A/zh active Pending
- 2002-09-20 CN CN 200510097948 patent/CN1810802B/zh not_active Expired - Fee Related
-
2004
- 2004-03-05 ZA ZA200401850A patent/ZA200401850B/en unknown
- 2004-03-05 ZA ZA200401845A patent/ZA200401845B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200401850B (en) | 2005-03-07 |
ZA200401845B (en) | 2005-03-07 |
CN1810802A (zh) | 2006-08-02 |
CN1810802B (zh) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100488958C (zh) | 3-取代的-4-嘧啶酮衍生物 | |
EP1427709B1 (en) | 3-substituted-4-pyrimidone derivatives | |
CN1764650B (zh) | 2,3,6-三取代的-4-嘧啶酮衍生物 | |
AU2002337499A1 (en) | 3-substituted-4-pyrimidone derivatives | |
AU2002337498A1 (en) | 3-substituted-4-pyrimidone derivatives | |
CN1726209B (zh) | 3-取代的-4-嘧啶酮衍生物 | |
CN1810802B (zh) | 3-取代的-4-嘧啶酮衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20081001 |